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Abstract
Treatment options for mesalamine-refractory ulcerative colitis (UC) include chronic immunosuppressive
medications or colectomy surgery. Current treatment paradigms presume the patients' foremost desire is to
avoid surgery and therefore view surgery as a consequence of medication failure. However,
immunosuppressive therapy may not be ideal for all patients due to unclear durable efficacy and potential
lethal serious adverse events (SAEs). We sought to quantify UC patients' risk tolerance of chronic
immunosuppression to avoid colectomy.
We first conducted a meta-analysis of all-cause and cause-specific mortality in both Crohn's disease (CD) and
UC, and examined the effect of study design on this outcome. We found elevated all-cause and cause-specific
mortality in both UC and CD including colorectal-, pulmonary- and non-alcoholic liver disease-related
relative mortality. We further found little evidence that study design impacted all-cause relative mortality
summary estimates.
We next conducted a study examining the reliability of the 6-Point Mayo score, a simple two-item non-
invasive non-physician driven index, for measuring UC disease activity. We found the 6-Point Mayo to
strongly correlate with more extensive disease assessment tools, with a similar sensitivity, specificity and ROC
area under the curve for patient-defined clinical remission.
With these insights, we conducted a discrete choice experiment to quantify the UC patients' mean maximum
acceptable risk for life-threatening SAEs associated with immunosuppressant therapy to avoid colectomy
surgery with various outcomes. We found that UC patient tolerance for medical and surgical risks do not
conform to conventional preference-elicitation methodology assumptions. UC patients were willing to accept
very high levels of fatal SAEs to avoid an ostomy. However, if a durable medication-induced remission could
not be achieved, patients were equally satisfied with J-pouch surgery. Several important clinical phenotypes
impacted patient risk tolerances. This is the first empirical demonstration that UC patients view a well-
functioning J-pouch as equivalent to mild clinical disease. It further demonstrates that patients value
medication efficacy and suggests that clinical remission, rather than response, be the preferred outcome for
therapy trials and treatment algorithms. Our findings underline the need for rigorous methodologies to
accurately measure patient-preferences; and suggest potential avenues to enhance UC patient autonomy and
facilitate shared decision-making.
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ABSTRACT 
 
WHAT IS YOUR COLON WORTH TO YOU?  CHANGING THE WAY WE LOOK AT 
ULCERATIVE COLITIS 
Meenakshi Bewtra 
James D. Lewis 
Treatment options for mesalamine-refractory ulcerative colitis (UC) include 
chronic immunosuppressive medications or colectomy surgery. Current treatment 
paradigms presume the patients’ foremost desire is to avoid surgery and therefore view 
surgery as a consequence of medication failure.  However, immunosuppressive therapy 
may not be ideal for all patients due to unclear durable efficacy and potential lethal 
serious adverse events (SAEs). We sought to quantify UC patients’ risk tolerance of 
chronic immunosuppression to avoid colectomy.   
We first conducted a meta-analysis of all-cause and cause-specific mortality in 
both Crohn’s disease (CD) and UC, and examined the effect of study design on this 
outcome.  We found elevated all-cause and cause-specific mortality in both UC and CD 
including colorectal-, pulmonary- and non-alcoholic liver disease-related relative 
mortality. We further found little evidence that study design impacted all-cause relative 
mortality summary estimates.   
We next conducted a study examining the reliability of the 6-Point Mayo score, a 
simple two-item non-invasive non-physician driven index, for measuring UC disease 
activity.  We found the 6-Point Mayo to strongly correlate with more extensive disease 
assessment tools, with a similar sensitivity, specificity and ROC area under the curve for 
patient-defined clinical remission. 
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With these insights, we conducted a discrete choice experiment to quantify the 
UC patients’ mean maximum acceptable risk for life-threatening SAEs associated with 
immunosuppressant therapy to avoid colectomy surgery with various outcomes.  We 
found that UC patient tolerance for medical and surgical risks do not conform to 
conventional preference-elicitation methodology assumptions.  UC patients were willing 
to accept very high levels of fatal SAEs to avoid an ostomy.  However, if a durable 
medication-induced remission could not be achieved, patients were equally satisfied with 
J-pouch surgery.  Several important clinical phenotypes impacted patient risk 
tolerances.  This is the first empirical demonstration that UC patients view a well-
functioning J-pouch as equivalent to mild clinical disease.  It further demonstrates that 
patients value medication efficacy and suggests that clinical remission, rather than 
response, be the preferred outcome for therapy trials and treatment algorithms.  Our 
findings underline the need for rigorous methodologies to accurately measure patient-
preferences; and suggest potential avenues to enhance UC patient autonomy and 
facilitate shared decision-making. 
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INTRODUCTION  
  
Overview of Ulcerative Colitis 
UC is a chronic relapsing remitting form of inflammatory bowel disease (IBD) with 
no known medical cure. UC affects over a half a million people in the United States 
alone and is rising in both incidence and prevalence.1  Patients with UC have 
inflammatory disease limited to their colon.  Disease activity can result in diarrhea, 
abdominal pain, anemia, fatigue, and other systemic symptoms.  Disease activity can 
range from remission (no symptoms) to moderate-severe (more than six bloody bowel 
movements a day with fevers, increased heart rate, and anemia) or even fulminant 
disease (more than ten bloody bowel movements a day, passage of blood alone from 
the rectum, anemia requiring blood transfusions, and severe abdominal pain).  These 
patients are additionally at risk for developing dilation of their colon that can result in 
perforation, with an extremely high morbidity and mortality.1-3  UC predominantly affects 
young adults in the 2nd and 3rd decade of life, resulting in significant economic burden 
from both chronic treatment and lost productivity. 
Surgical Treatment in Ulcerative Colitis 
UC patients are in a unique position because disease is limited to the colon; 
therefore surgery, specifically total proctocolectomy, provides a surgical “cure.”  The two 
most common operations performed for UC are total proctocolectomy with end ileostomy 
and restorative ileal pouch anal anastomsosis (IPAA).  The former entails a permanent 
ileostomy while the latter avoids this, but is associated with frequent bowel movements, 
the risk of pouchitis and the risk of fecal incontinence. 
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Risks of Surgical Treatment in Ulcerative Colitis 
Surgery has its own risks4-6; and quality of life following surgery is not perfect. 
Those having total proctocolectomy with end ileostomy will have a permanent external 
draining ileostomy.  Those having IPAA surgery still have six bowel movements a day on 
average.  This means that some patients will have more bowel movements than prior to 
their colectomy.  Additionally, patients with IPAA surgery are at risk for having fecal 
incontinence.   
Reported rates of serious infectious complications (including septic 
complications, pelvic abscesses and wound dehiscence) range from 1%-10% and may 
be institution and procedure-dependent, and related to pre-operative medication 
exposure (including corticosteroid use).4,6,7  Mortality rates with elective colectomy range 
are no higher than 1% at 35 months; and as low as 0.5% at 33 months.3-6     
Medical Treatment in Ulcerative Colitis 
Mesalamine (5-ASA) has proven to be a safe and effective therapy for UC.  
However, 5-ASA fails to induce a clinical remission in 50% or more of UC patients.8-14  
For patients in whom 5-ASA therapy is inadequate to control their disease, 
corticosteroids are frequently used.  Unfortunately, over 50% of patients either will suffer 
disease recurrence upon discontinuation of corticosteroids, or will be unable to taper off 
corticosteroids at all due to recurrent disease at lower doses of the drug.15   Therefore, 
alternatives to corticosteroid therapy have been developed.  Cyclosporine and 
tacrolimus have also been used as a bridge to immunomodulator therapy for refractory 
UC, particularly in patients who have failed to respond to intravenous corticosteroids.16,17  
Immunomodulators include the medications 6-mercaptopurine (6-MP) and its prodrug 
azathioprine.  These are thiopurine analogs that modulate the immune response by 
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inhibiting both T- and B-cell lymphocytes, interfering with natural killer cells, and 
inhibiting suppressor T-cell function and cell-mediated immunity18.  An alternative to the 
thiopurines include the anti-TNF medications including the medication infliximab, a 
chimeric monoclonal antibody that is 75% human and 25% murine19.  Infliximab targets 
tumor necrosis factor alpha (TNF-α), a pro-inflammatory cytokine that plays a central 
role in the initiation and promotion of the inflammatory cascade, and is a key mediator in 
several disease states including endotoxin-induced sepsis, rheumatoid arthritis, and the 
cachexia associated with malignancy.  Infliximab is approved by the FDA for treatment of 
UC.  Several other anti-TNF medications have more recently been approved or will likely 
be approved for UC, including adalimumab and golimumab (fully human monoclonal 
antibodies to TNF-α), and certolizumab pegol (a PEGylated Fab antibody fragment to 
TNF-α).   
Risks of Medical Treatment in Ulcerative Colitis 
While corticosteroids have been the mainstay of therapy for UC patients with 
disease flares, corticosteroids are associated with numerous well-characterized side 
effects with long-term use including near inevitable occurrence of bone disease and 
cataracts.  Corticosteroids have been associated with a 2-3 times increased odds of 
infection, including post-operative infections, serious infections and opportunistic 
infections.20-22  Finally, corticosteroids have been associated with an increased mortality 
risk.20,23   
Both the thiopurine analogs and anti-TNF medications suppress the immune 
system and modulate the inflammatory system in an attempt to reduce inflammatory 
activity in the colon and prevent relapses.  Because of the chronic nature of UC, these 
medications are for long-term use.   For those not pursuing definitive surgical treatment, 
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usage of these medications typically is planned for an indefinite duration.  Rates of 
infection for those on thiopurine analogs and anti-TNF therapy are as high as 5% per 
year.21,24-26  The thiopurine analogs and anti-TNF therapies also may increase the risk of 
certain cancers including an increased risk of cervical dysplasia and non-melanoma skin 
cancer.27-29    The risk of lymphoma associated with thiopurine analogs and anti-TNF use 
that may be as much as four times that of the general population; with combination 
therapy, this risk increases to 6-10 times that of the general population.30-33  A 
particularly aggressive and nearly universally fatal form of lymphoma, called 
hepatosplenic T-cell lymphoma (HSTCL), is associated with immunosuppression, 
particularly in young adults.34-36    By virtue of retaining their colon, IBD patients also 
have a lifetime risk of colon cancer that is as high as three times that of the general 
population. 37   
Despite this, UC patients treated with medical therapy were believed to have a 
normal life expectancy.  However, two recent studies question that assumption.  In a 
study by Roberts et al. examining patients who were admitted to the hospital in England 
for their UC, those patients pursuing chronic medical therapy had a two-times increased 
odds of mortality compared to those pursuing an elective colectomy surgery over the 
ensuing three years.38  A similar record-linkage study in Scotland found that those 
patients pursuing an elective colectomy had a significantly improved survival compared 
to those admitted emergently to the hospital for their UC, even after adjustment for age, 
gender and comorbidity status.39     
 Additionally, as with any medical therapies, there is the risk of medication failure 
with thiopurine analogs and anti-TNF’s.  In randomized-controlled trials of the thiopurine 
analogs for induction of remission for UC, there was no difference between the drugs 
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and placebo or mesalamine.18,40  In contrast, they have been shown to be effective as 
steroid sparing agents and in the maintenance of remission in ulcerative colitis, although 
in placebo-controlled studies, 36% failed to maintain remission at one year.18 
 Several clinical trials have evaluated the efficacy of infliximab in UC.  The two 
largest, Active Ulcerative Colitis Trials 1 and 2 (ACT 1 and ACT 2, respectively), 
evaluated the efficacy of infliximab for induction and maintenance of disease remission 
in UC.  In ACT 1, 69.4% of patients receiving 5mg/kg infliximab achieved and maintained 
remission at week 30, with similar findings reproduced in the ACT 2 trial.41  
Based upon these studies, at least one-third of patients who start 
immunomodulators or anti-TNFs will fail either induction or maintenance of remission.  
The consequences of incompletely treated disease as a result of medication failure are 
poorly understood.  However, indirect evidence suggests that these patients are at 
increased risk of morbidity and mortality.  In some, active UC can progress to severe or 
fulminant disease, and rarely perforation of the colon.  Therefore, these patients are at 
an increased risk of death from uncontrolled disease alone.  Patients who require an 
emergent colectomy have an immediate post-operative mortality rate between 0.6% and 
7.4%.3,42-44  Recently, in a sample representative of the U.S., it was shown that emergent 
colectomy had a substantially higher mortality rate than elective colectomy for UC.  In 
this study, the overall in-hospital mortality rate for UC patients undergoing an elective 
total abdominal colectomy was 0.7%; however, for those who had a colectomy following 
an emergent or urgent admission, the mortality rate was as high as 7.4%.3  Similarly, in a 
comparison of elective and emergent colectomy surgery in Britain, mortality rates three 
years after emergent colectomy were 13.2% compared to 3.7% for elective colectomy 
(adjusted odds ratio 3.04, p<0.001).38 
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Overview of Decision Making in Ulcerative Colitis 
If surgery for UC resulted in a completely normal quality of life, the choice 
between medical and surgical therapy would be obvious.  Because this is not the case, 
physicians and their patients have traditionally accepted the risks of medical therapies 
and considered surgery an option of “last resort.” At a national level, while 
immunosuppressant and prolonged corticosteroid use in UC has increased, surgical 
rates have not changed significantly over the past several decades or may be 
decreasing.45-47  The algorithm of making colectomy surgery the product of medication 
failure rests on the presumption that the patient’s foremost desire is to avoid surgery.  
However, for some patients, chronic immunosuppressive therapy may not be ideal due 
to unclear durable efficacy and potential lethal serious adverse events (SAEs).   
Because all potential therapies (medical and surgical) have potential risks and 
benefits, and thus implications for patient quantity and quality of life, patient collaboration 
in decision-making is essential.  The last few decades have seen an increased 
importance placed on patient preferences in healthcare.48,49  Patient preferences 
arguably play a critical role in health care outcomes, and an increasing premium is being 
placed on patient autonomy and shared decision-making:  patients’ preferences for 
therapies influence adherence, compliance and satisfaction with therapies, which in turn 
influences overall care.  In turn, understanding patient preferences for risks and benefits 
of therapies can inform physicians in their daily interaction with patients; regulators in 
setting thresholds for therapy efficacy and risk; and national organizations in setting 
treatment guidelines. Thus, rigorous methodologies capable of accurately quantifying 
patient preferences in large patient populations are needed to include UC patients’ 
voices in an increasingly complex decision process regarding their care. 
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Time Trade-Off and Standard-Gamble Studies in Ulcerative Colitis 
Health-state utility is a well-known cardinal index of the quality of a given health 
state. Utilities can be measured at population or individual levels, and vary as people’s 
health changes. Changes in health states can be expressed as incremental utility elicited 
by either time-tradeoff or standard-gamble question formats.  Utilities can be converted 
to quality-adjusted life years (QALYs) that are used in cost-utility analysis. QALYs weight 
durations in each health state by the average utility of that state and facilitate health-
outcome comparisons across groups of people, health outcomes and durations. 
In time-trade-off (TTO) studies, respondents evaluate specific treatment-outcome 
scenarios and are asked how much of a reduction in expected life years they would 
accept for living in perfect health instead of living the rest of their expected lifetime in the 
compromised health state. Health-state utility is measured as the ratio of equivalent 
years in perfect health to years in compromised health. 
Standard-gamble (SG) studies elicit the highest level of risk of the worst 
imaginable health state (usually assumed to be death) respondents would accept in 
return for best possible health. Setting the utility of death at zero and the utility of best 
possible health at 1, and assuming that expected utility is the sum of outcomes weighted 
by probabilities, one minus the indicated risk of death indicates the health-state utility. 
A number of TTO and SG studies have evaluated preferences of UC patients for 
continued medical management of UC versus colectomy surgery.50-54  Overall, these 
studies suggest that UC patients view colectomy surgery and the post-surgery state with 
significantly diminished quality of life, thus supporting current treatment algorithms of 
making colectomy surgery an option of last resort.  However, at least one of these 
studies found that optimal utility (used in Markov modeling for various treatment 
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decisions) was highly variable among UC patients with total colectomy being the optimal 
treatment choice for 37% of their patient sample.  When utilizing the average utility for 
analysis, medical therapy was superior to colectomy surgery.  However, this substantial 
variability in utilities was reflected in their sensitivity analysis, in which only one-third of 
patients had highly reliable optimal treatment decisions in modeling.50 
Limitations of Time Trade-Off and Standard-Gamble Studies in Ulcerative Colitis 
Using traditional methods such as TTG and SG to obtain utility values for QALY 
estimation has been widely accepted for health-technology assessment because these 
methods allow for a simple method of integrating mortality, morbidity and preferences for 
therapies into a single estimation representing the equivalent years of perfect health.  
This allows for relatively simple comparisons with other QALY-based measurements 
(including some quality of life questionnaires) and utilization of these QALYs for cost-
utility analyses. 
However, it is this simplicity that can become problematic due to inaccurate 
assumptions regarding patient preferences.  TTO and SG studies suffer from a number 
of fundamental limitations that have been recognized for several decades.55-59  The 
clinically-artificial method of eliciting patient utilities in TTO/SG studies employs cardinal-
utility, a ratio-scale metric rejected by nineteenth-century utility theorists in favor of 
ordinal-utility measures. Ordinal utility is the basis of virtually all subsequent applied-
economics research.60   
Numerous validity tests of QALY studies also have rejected the assumptions of 
independence, procedural and description invariance, linearity over time and 
comparability across groups of patients.61,62  Furthermore, in the interest of simplicity, 
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conventional TTO and SG applications assume that health history or current health state 
do not affect relative preferences.  Moreover, conventional health-state utility 
measurement techniques are unable to capture the impact of acute conditions, treatment 
risks, or process-related factors such as the method of administration or treatment 
duration.  Such factors can play a significant role in understanding UC patients’ 
preferences for treatments. 
Discrete Choice Experiments  
Discrete choice experiments (DCEs; also known as choice-format conjoint 
analysis) employ a multi-attribute preference-elicitation technique that quantifies the 
strength of preferences for features of products, services or health-care interventions.   
Interventions, such as medical or surgical treatments in IBD, derive value from their 
specific attributes, features or outcomes, including treatment efficacies, tolerability, 
convenience, and potential SAE risks.  In turn, each of these attributes has varying 
levels, such as efficacy rates or adverse risk rates.  DCEs recognize that patients have 
preferences of varying strengths for different attributes and are willing to accept tradeoffs 
among various levels.  DCEs systematically elicit tradeoffs among constructed outcome 
combinations to generate choice data that quantifies implicit decision weights indicating 
relative utility for both individual treatment attributes (such as the specific risks and 
benefits) as well as the treatment option as a whole.  Because DCEs measure the rate 
at which patients accept tradeoffs among different treatment attributes, it is also possible 
to calculate a maximum acceptable risk or maximum probability of an adverse event that 
participants are willing to tolerate in exchange for a given treatment benefit.  DCE 
increasingly has been applied in the field of healthcare for eliciting patient preferences 
for a range of medical and surgical therapies across many disease states.63-69   
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Advantages of Discrete Choice Experiments  
 One of the most powerful advantages of DCE is that it does not require the 
restrictive assumptions of conventional QALY metrics.  By offering realistic benefit-risk 
tradeoff scenarios within a non-expected utility framework, DCEs more accurately 
quantify preference data, from which utility is derived.  Houtven et al. showed how to 
derive maximum acceptable risk from generalized utility theory with an example using a 
DCE study in IBD.62 
As patient preferences play a key role in patient satisfaction, which in turn 
influences adherence and ultimately clinical outcomes, DCE-measured preference data 
are more patient-centered than QALYs.  Furthermore, by measuring preferences for 
attributes of a medical therapy as well as the therapy overall, DCE also provides 
information on the total value of an intervention or on the marginal effect of modifying a 
single factor on the value.  By collecting data within carefully devised experimental 
designs, DCEs can introduce variability and reduce or even completely eliminate 
collinearity, making possible more precise estimates of attribute contributions to therapy 
utilities.  This also allows for preference measurement on future interventions including 
those that may not be currently available.  This, in turn, can allow quantification of 
patients’ risk thresholds that can help physicians, drug manufacturers and regulators 
when contemplating appropriate indications for existing or new therapies, or treatment 
algorithms. 
The majority of DCE studies in IBD have been done in Crohn’s disease, another 
type of IBD that can occur throughout the GI tract.  These robust studies have examined 
CD patients preferences for therapy goals; willingness to accept life-threatening SAEs in 
exchange for medication efficacy; and variations in preferences by providers and 
patients.  In UC, DCE has been used to evaluate UC patient preferences for various 
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aspects of 5-ASA therapy.70  No prior DCE analysis, however, has examined the risk 
tolerance UC patients have for escalation of medical therapy versus colectomy surgery, 
a central issue for over 50% of UC patients whose disease cannot be controlled with 5-
ASA therapy alone.   
Summary  
With an increasing number of immunosuppressant medical therapies being 
offered, rigorously quantifying UC patients’ risk tolerances includes their voice in an 
increasingly-complex treatment paradigm.  Identifying patient subgroups that are more 
or less willing to accept surgery can inform physicians caring for these patients.  
Determining risk and efficacy levels for which colectomy surgery is preferable to medical 
therapy can inform drug efficacy trials and treatment algorithms in UC.     
A conceptual model of our thesis studies is shown in Figure 1.1.  We 
hypothesized that UC patients perceive the benefits of medical versus surgical therapy 
and have a quantifiable risk tolerance for medical therapy SAEs in preference to 
colectomy surgery; however, this tolerance is modified by both clinical factors (e.g. age, 
gender, disease duration, disease activity, etc.) as well as treatment factors (efficacy, 
surgical outcome).  To test this hypothesis, we use DCE to determine the mean 
maximum acceptable risk (MAR) for SAEs associated with immunosuppressant therapy 
in UC that patients are willing to accept to avoid colectomy with ostomy, IPAA or IPAA 
complicated by fecal incontinence.  We also evaluated how clinical characteristics and 
therapy efficacy affect tolerance for medical therapy risks in preference to surgery 
(Chapter 4).   
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In developing the DCE survey instrument, we additionally conducted two 
separate but related studies.  To limit cognitive burden and numeracy concerns, 
specifically confusion over conditional probabilities (the probability of an SAE conditional 
on the probability of having the outcome), we sought to describe all treatment benefits as 
certain and all treatment risks as known probabilities.  One such attribute was that of 
mortality from colorectal cancer, a risk associated with pursuance of medical therapy 
(and retention, therefore, of one’s colon).  While prior work had demonstrated an up to 
three-times increased risk of colon cancer development in UC patients compared to the 
general population,37 no evidence existed regarding the risk of colon cancer mortality in 
UC.  Single-center studies are often underpowered when examining outcomes such as 
mortality.  Meta-analysis is a statistical methodology for combining similar studies to 
obtain more precise effect estimates.  However, prior meta-analyses examining this 
issue have come to inconsistent conclusions.71-74  Furthermore, some meta-analyses 
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have included only population-based studies, others only inception cohorts; none of the 
recent meta-analyses have included referral center-based studies; and many neglected 
to examine specific causes of death including colorectal cancer.  Therefore, we 
undertook a meta-analysis of all-cause mortality and cause-specific mortality related to 
colorectal cancer, non-alcoholic liver disease, pulmonary disease and cardiovascular 
disease in both UC and CD (Chapter 2).  Additionally, we sought to determine how 
results of population-based studies, inception cohorts, and single- or multi-center studies 
vary. 
We also hypothesized that one clinical factor affecting risk tolerance in UC would 
be disease activity at the time of DCE survey completion.  Currently, no gold-standard 
for disease activity severity assessment in UC exists.  However, at least 14 disease 
activity indices do exist, many of which include invasive testing, laboratory tests, and/or 
physician assessment that can make studies costly, difficult to implement and can deter 
patient enrollment, especially with repeated measurements.75  Purely patient-driven 
disease assessment indices include the Simple Clinical Colitis Activity Index (SCCAI), 
which has been shown to have robust validity and reliability.76,77  While the SCCAI is 
completely patient-driven, it includes some variables such as extra-intestinal 
manifestations that may be ambiguous to patients and thus cause incorrect patient-
reporting of current disease activity.  Additionally, the quantity of questions in the SCCAI 
can make it cumbersome in studies with repeated measurements.   
In contrast, a purely patient-driven 6-Mayo score has been infrequently utilized in 
clinical research studies in UC.  Two prior studies have found that the 6-Point Mayo 
score correlates well with the full Mayo Clinic Score, an index most commonly used in 
clinical trials but requiring both a flexible sigmoidoscopic and physician evaluation.78,79  
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However, no studies had sought to correlate the 6-Point Mayo with disease severity 
indices outside of the Mayo scoring system.  We hypothesized that the much-simpler 
two-question 6-Point Mayo would have comparable sensitivity, specificity and receiver 
operating characteristic (ROC) area under the curve for patient-defined clinical remission 
as the SCCAI.  We therefore sought to evaluate how the 6-Point Mayo score correlated 
with the SCCAI and a single Likert-scale of patient defined disease activity (Chapter 3).  
We further sought to perform a validation study in a separate patient population. 
The results of these studies have several important implications.  For UC 
patients, and the physicians and surgeons caring for them, these results provide 
information regarding disease outcomes, improve understanding of UC patient risk 
tolerances, and provide avenues for enhancing informed consent and shared decision-
making for UC patients.  For clinical researchers, findings from these studies provide 
avenues for simpler non-invasive disease severity assessment.  The results of these 
studies also set new thresholds for therapies and therapeutic guidelines in UC.  Finally, 
our findings inform future funding proposals aimed at evaluating causes of morbidity and 
mortality in IBD, measuring activity in UC, and assessing the impact of interventions 
such as education on IBD patient risk tolerances. 
  
15 
 
CHAPTER 2:  Crohn’s Disease and Ulcerative Colitis Are Associated with Elevated 
Standardized Mortality Ratios:  A Meta-Analysis 
 
Short Title:  IBD Mortality Meta-Analysis 
Authors:  Bewtra, Meenakshi*#†; Kaiser, Lisa**; TenHave, Tom*#†; Lewis, James D*#† 
*University of Pennsylvania – Department of Medicine 
** Hospital of the University of Pennsylvania 
#University of Pennsylvania – Department of Biostatistics and Epidemiology 
†University of Pennsylvania – Center for Clinical Epidemiology and Biostatistics 
Abbreviations:  Crohn’s disease (CD); inflammatory bowel disease (IBD); standardized 
mortality ratio (SMR); ulcerative colitis (UC) 
Correspondence:  Meenakshi Bewtra, 423 Guardian Drive, 724 Blockley Hall, Phila, PA  
19104-6021; fax number 215-573-5325; telephone 215-746-4922; email  
meenakshi.bewtra@uphs.upenn.edu 
Disclosures:  all authors have nothing to disclose 
Author Contributions:   
Meenakshi Bewtra:  study concept and design, paper reviewer, analysis and 
interpretation of data, drafting of manuscript, critical revision of manuscript, statistical 
analysis 
Lisa Kaiser:  paper reviewer, interpretation of data; critical revision of manuscript 
16 
 
Tom TenHave:  statistical analysis, drafting of manuscript; critical revision of manuscript 
James D. Lewis:  study concept and design, paper reviewer, analysis and interpretation 
of data, drafting of manuscript, critical revision of manuscript 
17 
 
Abstract: 
Background: 
Evidence regarding all-cause and cause-specific mortality in inflammatory bowel disease 
(IBD) is conflicting, and debate exists over appropriate study design to examine these 
important outcomes.  We conducted a comprehensive meta-analysis of all-cause and 
cause-specific mortality in both Crohn’s disease (CD) and ulcerative colitis (UC), and 
additionally examined various effects of study design on this outcome. 
Methods: 
A systematic search of PubMed and EMBASE was conducted to identify studies 
examining mortality rates relative to the general population.  Pooled summary 
standardized mortality ratios (SMR) were calculated using random effects models. 
Results: 
35 original articles fulfilled the inclusion and exclusion criteria, reporting all-cause 
mortality SMRs varying from 0.44 to 7.14 for UC; and 0.71-3.20 for CD.  The all-cause 
mortality summary SMR for inception- and population-cohort UC studies was 1.19 (95% 
CI 1.06-1.35).  The all-cause mortality summary SMR for inception- and population-
cohort CD studies was 1.38 (95% CI 1.23-1.55).  Mortality from colorectal cancer, 
pulmonary disease and nonalcoholic liver disease was increased whereas mortality from 
cardiovascular disease was decreased.     
Conclusions: 
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Patients with UC and CD have higher rates of death from all causes, colorectal-cancer, 
pulmonary disease, and nonalcoholic-liver disease.   
 
Key words:  inflammatory bowel disease, ulcerative colitis, Crohn’s disease, mortality, 
meta-analysis 
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Introduction: 
Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and 
ulcerative colitis (UC), are chronic intestinal inflammatory diseases.  Due to the chronic 
and sometimes severe nature of this disease, there is obvious need to elucidate both all-
cause and cause-specific mortality, as this has important implications for patients and 
more globally for issues such as public health planning.   
Meta-analysis is a statistical methodology for combining similar studies to obtain 
a more precise effect estimate.  Prior meta-analyses examining this issue have come to 
inconsistent conclusions, perhaps because of different inclusion criteria (Table 2.1).71-74   
TABLE 2.1:  Prior meta-analyses of IBD mortality 
 IBD 
type 
Included studies 
(publication 
year) 
Outcomes SMR (95% CI) 
Canavan et al., 
200771 
CD All study types 
(1980-2004) 
All-cause mortality 1.52 (1.3-1.7) 
Dorn et al., 
200772 
CD 
UC 
All study types 
(1981-2006) 
Cardiovascular mortality (0.8-1.1) 
0.9 (0.8-1.0) 
Jess et al., 
200773 
UC Inception-cohort 
studies 
(1982-2005) 
All-cause mortality 
CRC mortality 
Cardiovascular mortality 
Respiratory disease 
mortality 
Non-alcoholic liver disease 
mortality 
1.1 (0.9-1.2) 
1.9 (1.0-3.8) 
0.9 (0.7-1.1) 
1.6 (1.3-2.0) 
4.0 (2.5-6.5) 
Duricova et al., 
201074 
CD Population-based 
studies 
All-cause mortality 
All-cause cancer mortality 
Pulmonary cancer mortality 
Malignant melanoma 
mortality 
CRC mortality 
Pulmonary mortality 
1.39 (1.3-1.5) 
1.50 (1.2-1.9) 
2.72 (1.4-5.5) 
10.0 (1.2-36.1) 
1.3 (0.5-3.3) 
1.4 (0.7-2.2) 
Specifically, some meta-analyses have included only population-based studies, 
others only inception cohorts; and none of the recent meta-analyses have included 
referral center-based studies.  Furthermore, many focused only on all-cause mortality 
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neglecting specific causes of death, critical information if one is to plan interventions to 
reduce IBD-related mortality.   
Therefore, we undertook a meta-analysis of all-cause mortality and cause-
specific mortality related to colorectal cancer, non-alcoholic liver disease, pulmonary 
disease and cardiovascular disease in both UC and CD.  Additionally, we sought to 
determine how results of population-based studies, inception cohorts, and single- or 
multi-center studies vary. 
Materials and Methods: 
Search strategy: 
To identify published studies on this topic, a systematic search of PubMed  was 
performed on November 12, 2011.  The search used the keywords and MESH headings 
inflammatory bowel disease or ulcerative colitis or Crohn’s disease combined with 
colorectal cancer or colon cancer or rectal cancer or pulmonary disease or 
cardiovascular disease or hepatic disease or mortality or death or survival.  A 
comprehensive search of reference lists in prior meta-analyses and original studies 
retrieved by this method was performed to identify additional reports.  This approach 
identified 15,577 papers published between 1941 and 2011.  Application of the 
limitations “English language journal papers” and “human studies” yielded 11,234 papers 
for analysis (Figure 2.1).  An search of EMBASE using the same keywords and MESH 
headings was performed and no additional appropriate papers were identified.   
Inclusion and exclusion criteria: 
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 Only full length peer-reviewed English language or English-translated papers 
reporting observational study results were included to allow full evaluation of study 
methods and results (such as study inclusion criteria, follow-up time, specific details of 
how cause specific mortality was determined, methods of ascertainment of data and 
calculation of outcome measures).  All-cause and/or cause-specific mortality had to be 
reported as either standardized mortality ratio (SMR), relative risk (RR), incidence rate 
ratio (IRR), hazard ratio (HR) or odds ratio (OR) with or without 95% confidence 
intervals.  When two or more publications reported on the same patient population only 
the most recent study results were included.  Application of these criteria resulted in 35 
original papers for 
analysis (Figure 2.1).   
Data Collection: 
 Included papers 
were reviewed in detail by 
two reviewers (MB and 
either LK or JDL; 
discrepancies were 
decided by concensus 
and if necessary by the 
third reviewer JDL) to 
determine number of 
patients, gender distribution, number of UC and CD patients, calendar year of 
publication, decade of the middle year of patient observation, mortality rates and/or 
observed and expected numbers of deaths, 95% confidence intervals, region of IBD 
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population, type of study population and study design.  In two studies, a lower 95% CI of 
0.0 was reported.80,81  To allow this to be included in the summary calculations, we 
approximated the lower bound to 0.025 (i.e. the midpoint between 0 and 0.049).  
 Studies were categorized into the following groups based on the source of the 
study population:  single or multi-center study if all patients observed came from the 
same center or group of physicians; population-based if the IBD population was 
identified within a defined geographic area; inception cohort if it was explicitly stated that 
patients received their initial IBD diagnosis during their time within the cohort or if the 
study explicitly stated it was a population-based inception cohort.   
Statistical Analysis: 
 The outcome of interest was the relative mortality rate as compared to the 
general population and respective 95% CIs. In the event that 95% CIs were not 
calculated but observed and expected values were given, 95% CIs were calculated 
using the Rothman-Greenland method.   Because all but one study reported results in 
terms of the SMR, we used this as our summary measure of relative risk.  Pooled SMRs 
with 95% CI for all-cause and cause-specific mortality were calculated using STATA’s 
metan command, which uses the DerSimonian and Laird method, a random- effects 
model that incorporates both between-study and within-study variation. 
Statistical heterogeneity was assessed two ways.  First, the I2 index and χ2 test 
were used to investigate differences among studies with respect to SMRs.  Additionally, 
sub-group analyses were performed to assess potential sources of heterogeneity 
separately due to the following available patient- and study-level factors:  region of 
study, study type, and decade of the middle year of patient observation.  Meta-
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regression analysis was also performed for heterogeneity of the all-cause SMR due to 
cohort size and middle year of patient observation.  Cumulative meta-analysis was 
performed to examine all-cause mortality.  Funnel plots of the log SMR versus its 
standard error were performed to assess publication bias for analyses with five or more 
studies.  Begg’s rank correlation method and Egger’s regression were used to test the 
correlation between effect and sample size. 
Ethical Considerations:  The study protocol was reviewed by the Institutional Review 
Board at the University of Pennsylvania and met the criteria for exempt status. 
Results: 
Study Characteristics:   
 A total of 35 studies were included, of which 10 were inception cohorts, 13 were 
population-based cohort studies, 8 were single-center studies, and 4 were multi-center 
studies (Table 2.2).  These studies included all studies used in prior meta-analyses 
excluding one abstract used in a meta-analysis by Jess et al.73 and one study used in 
the meta-analysis by Canavan et al for which data were not available.71,82 
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TABLE 2.2:  Studies included in meta-analysis 
Study Location Median 
Follow-up 
(months) 
Study 
Source 
Population 
Size 
Mortality 
studied 
Romberg-
Camps 
(2010)81 
Netherlands 67.2-93.6 Inception 
cohort 
UC: 630 
CD: 476 
All-cause 
CV 
Pulmonary 
Solberg 
(2009)83 
Norway Not reported Inception 
cohort 
UC: 519 
CD: 237 
All-cause 
Hutfless 
(2007)84 
N. America 81.6 Population-
based 
UC: 5238 
CD: 3241 
 
All-cause 
CRC 
CV 
Pulmonary 
Hepatic 
Canavan 
(2007)85 
UK 288 Population-
based 
CD: 394 All-cause 
Park (2007)86 Korea 62.5 Single center UC: 304 All-cause 
Jess (2007)87 Denmark Not reported Inception 
cohort 
UC: 1575 
CD: 641 
All-cause 
 
Hoie (2007)88 EC-IBD 35 Inception 
cohort 
UC: 775 All-cause 
CV 
Pulmonary 
Delaunoit 
(2006)89 
N. America Not reported Single center UC: 249 
CD: 49 
CRC 
Jess (2006)90 N. America 168 Inception 
cohort 
UC: 378 
CD: 314 
All-cause 
CV 
Pulmonary 
Wolters 
(2006)91 
EC-IBD 372 Inception 
cohort 
CD: 371 All-cause 
CV 
Pulmonary 
Masala 
(2004)92 
Italy 177.6 Population 
cohort 
UC: 689 
CD: 231 
All-cause 
CRC 
CV 
Card (2003)93 UK Not reported Population- 
based 
UC: 8301 
CD: 5960 
All-cause 
Winther 
(2003)94 
Denmark 228 Inception 
cohort 
UC: 1160 All-cause 
CRC 
CV 
Pulmonary 
Liver 
Uno (2003)95 Japan Not reported Multi-center CD: 544 All-cause 
CRC 
Jess (2002)96 Denmark 204 Inception 
cohort 
CD:  374 All-cause† 
CV 
Pulmonary 
Viscido 
(2001)80 
Italy 73.2 Multi-center UC:  2066 All-cause 
CRC 
CV 
Pulmonary 
Liver 
Farrokhyar 
(2001)97 
UK 99.6 Inception 
cohort 
UC: 365 
CD: 196 
All-cause 
Katoh 
(2000)98 
Japan Not reported Single center UC: 117 All-cause 
Ishibashi 
(1999)99 
Japan 192 (UC) 
188.4 (CD) 
Population 
cohort 
UC: 174 
CD 66 
All-cause 
CRC 
Saro (1999)100 Spain Not reported Population 
cohort 
UC: 261 
CD: 259 
All-cause 
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Palli (1998)101 Italy 
 
 
121.2 Population 
cohort 
 
UC: 689 
CD: 231 
All-cause†† 
CRC 
CV 
Pulmonary 
Davoli 
(1997)102 
Italy 60 Single center UC:  508 All-cause 
CV 
Persson 
(1996)103 
Sweden Not reported Inception 
cohort 
UC: 1547 
CD: 1251 
All-cause 
CRC 
CV 
Pulmonary 
Liver 
Cottone 
(1996)104 
Southern 
Europe 
93.6 Single center CD: 531 All-cause 
CRC 
Stewenius 
(1995)105 
Sweden Not reported Population 
cohort 
UC:  462 All-cause 
Pulmonary 
Probert 
(1993)106 
UK Not reported Population 
cohort 
UC:  1014 All-cause 
Ekbom 
(1992)107 
Sweden Not reported Population 
cohort 
UC: 3121 
CD: 1655 
All-cause 
CRC 
CV 
Pulmonary 
Hepatology 
Probert 
(1992)108 
UK Not reported Population 
cohort 
CD: 610 All-cause 
Weterman 
(1990)109 
Netherlands Not reported Single center CD: 671 All-cause 
Gyde 
(1982)110 
UK 189.6 Multi-center UC: 676 All-cause 
CV 
Pulmonary 
Eason 
(1982)111 
New Zealand 72 Multi-center UC: 456 
CD: 137 
All-cause 
CRC 
CV 
Prior (1981)112 UK Not reported Single center CD: 513 All-cause 
CV 
Pulmonary 
Ritchie 
(1978)113 
UK Not reported 
 
Single center UC: 269 All-cause 
Gilat (1976)114 Israel 93.6 Population 
cohort 
UC: 504 All-cause 
Iversen 
(1968)115 
Denmark Not reported Population 
cohort 
 
UC: 231 All-cause 
*CRC: colorectal cancer; CV: cardiovascular 
† Given more recent all-cause mortality rates for this population, only pulmonary and cardiovascular 
mortality was used in the current study 
†† Given more recent all-cause, CRC and CV mortality rates for this population, only pulmonary mortality 
was used in the current study 
 
 Overall, there were 32,269 patients with CD and 18,952 patients with UC.  The 
year of publication ranged from 1968-2010.  The median duration of follow-up (when 
provided) was 83.4 months for UC and 204 months for CD. 
All-cause Mortality 
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 The reported SMRs for all-cause mortality in patients with UC ranged from 0.44 
(95% CI 0.12-1.12) to 7.14 (95% CI 1.47 to 20.70).86,100  The all-cause mortality 
summary SMR for UC was 1.16 (95% CI 1.04-1.29) (Table 2.3). When combining 
inception cohort and population-based studies, the all-cause mortality summary SMR for 
UC was 1.19 (95% CI 1.06-1.35).   
TABLE 2.3:  Standardized Mortality Ratios 
 SummarySMR L95% U95% I2 Het p-value # studies 
Overall:  UC  1.16 1.04 1.29 84% 0.00 25 
Overall:  CD 1.46 1.30 1.63 71% 0.00 19 
       
Colorectal 
cancer:  UC 
2.82 1.68 4.74 80% 0.00 7 
Colorectal 
cancer:  CD 
3.12 0.97 10.10 73% 0.00 6 
       
Cardiovascular 
disease:  UC 
0.90 0.80 1.02 39% 0.09 11 
Cardiovascular 
disease:  CD 
1.00 0.88 1.13 0.0% 0.73 9 
       
Pulmonary 
disease: UC 
1.41 1.12 1.77 39% 0.10 10 
Pulmonary 
disease:  CD 
1.60 1.24 2.05 0.0% 0.43 8 
       
Nonalcoholic 
liver disease: 
UC 
2.26 1.14 4.49 55% 0.06 5 
Nonalcoholic 
liver disease:  
CD 
2.82 1.52 5.21 0.0% 0.63 3 
 
 The reported SMRs for all-cause mortality in CD patients ranged from 0.71 (95% 
CI 0.51-1.01) to 3.20 (95% CI 0.38-11.50).100,108  The all-cause mortality summary SMR 
for CD was 1.46 (95% CI 1.30-1.63) (Table 2.3).  When combining inception cohort and 
population-based studies, the all-cause mortality summary SMR for CD was 1.38 (95% 
CI 1.23-1.55).   
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 There was significant heterogeneity in the all-cause summary SMR across levels 
of patient- and study-level factors for both UC and CD (Table 2.4).  Twelve studies 
reported on gender-specific overall mortality for UC and CD, with a possible trend 
towards higher relative mortality in females (Table 2.4).  However, there remained 
significant among-study heterogeneity when examining men and women separately. 
TABLE 2.4:  All-Cause Standardized Mortality Ratios*†  
  Pooled 
ES 
L95% U95% I2 Het p-
value 
# 
studies 
 UC       
Men  1.10 0.94 1.28 56% 0.01 12 
Women  1.29 1.01 1.64 76% 0.00 12 
 CD       
Men  1.32 1.11 1.57 55% 0.01 12 
Women  1.63 1.38 1.93 57% 0.01 12 
 UC 
all-cause 
      
North America  0.92 0.74 1.14 55% 0.14 2 
United Kingdom  1.21 0.96 1.54 86% 0.00 5 
North Europe  1.23 1.10 1.40 79% 0.00 8 
South Europe  1.01 0.69 1.49 80% 0.00 4 
Other countries  1.14 0.65 2.01 76% 0.00 5 
EC-IBD  1.09 0.86 1.38 ….. ….. 1 
 CD 
all-cause 
      
North America  1.36 1.19 1.54 0% 0.35 2 
United Kingdom  1.30 0.99 1.72 90% 0.00 5 
North Europe  1.54 1.29 1.84 73% 0.01 5 
South Europe  1.62 1.23 2.14 0% 0.62 3 
Other countries  1.29 0.72 2.33 0% 0.89 3 
EC-IBD  1.85 1.30 2.55 ….. ….. 1 
 UC 
all-cause 
      
Inception   1.08 0.97 1.21 67% 0.00 8 
Population   1.32 1.07 1.63 90% 0.00 10 
Single-center   1.03 0.77 1.38 22% 0.28 4 
Multi-center   1.16 0.73 1.83 90% 0.00 3 
All-studies  1.16 1.04 1.29 84% 0.00 25 
 CD 
all-cause 
      
Inception   1.34 1.15 1.56 49% 0.08 6 
Population   1.39 1.18 1.64 77% 0.00 8 
Single-center   2.06 1.78 2.38 0% 0.68 3 
Multi-center   1.25 0.67 2.32 0% 0.67 2 
All-studies  1.46 1.30 1.63 71% 0.00 19 
 UC 
all-cause 
      
Decade 2000s  0.44 0.12 1.12 …. …. 1 
Decade 1990s  1.04 0.83 1.31 90% 0.00 6 
Decade 1980s  1.05 0.99 1.12 0% 0.77 7 
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Decade 1970s  1.21 1.01 1.45 74% 0.00 8 
Decade 1960s  2.26 1.79 2.86 0% 0.42 2 
Decade 1950s  1.70 1.48 2.06 ….. ….. 1 
 CD 
all-cause 
      
Decade 2000s  ….. ….. ….. ….. ….. 0 
Decade 1990s  1.54 1.32 1.79 54% 0.07 5 
Decade 1980s  1.14 0.84 1.55 62% 0.02 6 
Decade 1970s  1.42 1.27 1.59 35% 0.18 6 
Decade 1960s  2.09 1.79 2.43 0% 0.49 2 
Decade 1950s  ….. …… ….. ….. …. 0 
*Numbers of studies reporting from respective regions of the world:  North America (3); United Kingdom (8); 
Northern Europe (9); Southern Europe (6); Other Regions (6); European Collaborative Study Group of 
Inflammatory Bowel Disease (EC-IBD) (2) 
† Decade refers to decade of the middle year of patient observation in study 
 
Meta-regression was carried out to explore evidence that between-study 
heterogeneity could be due to cohort size or decade of the middle year of patient 
observation, two variables universally available in all studies.  For all-cause mortality in 
UC and CD, the SMR was not associated with cohort size (p=0.71 and p=0.43 
respectively) or decade of middle year of patient observation (p=0.06 and p=0.28 
respectively).   
 Subgroup analyses were performed stratified by geographic region (Table 2.4).  
Despite the reduced number of studies, there remained significant heterogeneity in most 
of the regional subgroup analyses for all-cause mortality. 
Study Type 
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 Figure 2.2 shows the similarity of the population-based studies and inception 
cohort studies examining all-cause mortality in UC.  Inception cohort, single-center and 
multi-center studies all showed non-significant SMRs of similar elevated magnitude 
[summary SMRs 1.08 (95% CI 0.97-1.21), 1.03 (95% CI 0.77-1.38) and 1.16 (95% CI 
0.73-1.83) respectively)].  A significantly elevated SMR was observed for population-
based studies (summary SMR 1.32, 95% CI 1.07-1.63) (Table 2.4).  However, this 
estimate fell within the range of mortality estimates for other study types and there 
remained significant heterogeneity within the subgroup of population-based studies 
(Table 2.4 and Figure 2.2).  Therefore, heterogeneity of the all-cause mortality summary 
estimate could not be accounted for by study type for UC.   
For all-cause mortality in CD, higher SMRs were reported in single-center studies 
than for inception or population based studies [(summary SMRs 2.06 (95% CI 1.78-
2.38), 1.34 (95% CI 1.15-1.56) and 1.39 (95% CI 1.18-1.64) respectively)].  Multi-center 
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studies had a non-significant all-cause summary SMR of 1.25 (95% CI 0.67-2.32).  
These data suggest that heterogeneity among CD studies was partly explained by 
inclusion of single-center studies.  However, significant heterogeneity remained in the 
inception and population-based studies (p=0.08 and p ≤ 0.01 respectively). 
 Cumulative meta-analysis was carried out to examine how the summary mortality 
estimate for all-cause mortality in UC and CD changed with successive published 
inception and inception plus population-based cohort studies (see Figure 2.3).  For UC, 
the dates of inception-cohort studies ranged from 1996 to 2010; and ranged from 1968 
to 2009 for population-based cohort studies.  The summary mortality estimate for both 
study cohort types was attenuated over time (see Figure 2.3).  In the inception cohort 
only studies, the summary mortality estimate became non-significant over time (SMR 
1.08, 95% CI 0.97-1.21).  The addition of population cohort studies yielded a very similar 
summary estimate that remained slightly elevated over time (SMR 1.17, 95% CI 1.04-
1.32).   Additional cumulative meta-analysis was performed removing the studies from 
1968 and 1976; the resulting dates of studies ranged from 1992-2010.  The summary all-
cause mortality estimates remained very similar to that of inception-only studies (SMR 
1.10, 95% CI 0.99-1.23).   
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For CD, inception cohort-only studies ranged from 1996-2010; with the addition 
of population cohort studies, the date of the studies ranged from 1992-2010 (see Figure 
2.3).  The summary mortality estimate for all-cause mortality remained fairly constant 
over time for both inception cohort studies alone and inception plus population cohort 
studies (SMR 1.34, 95% CI 1.15-1.56; and SMR 1.37, 95% CI 1.22-1.53 respectively). 
Analysis of Cause Specific Mortality 
 Significantly elevated SMRs for colorectal cancer, pulmonary disease, and 
nonalcoholic liver disease were observed in UC; and significantly elevated SMRs for 
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pulmonary disease and nonalcoholic liver disease were observed in CD (Table 3).  
However, for patients with UC and CD, the SMR for cardiovascular disease related 
mortality rates was not significant; and for patients with CD, the SMR for colorectal 
cancer mortality was not significant, although there appeared to be a trend towards 
significance.  Significant heterogeneity was observed for CRC-related mortality in UC 
and CD.  There was borderline heterogeneity for hepatic- and cardiovascular-related 
mortality in UC (Table 2.3).  Because of the small number of studies, all study types 
were included in cause specific mortality analysis (Table 2.3); and only qualitative 
comparisons were made across geographic region or study type for cause specific 
mortality (Table 2.5).  Differences in definitions of cause specific mortality are 
summarized in Table 2.6. 
Table 2.5. Cause-specific Standardized Mortality Estimates*† 
  Summary 
SMR 
L95% U95% I2 Heterogeneity  
p-value 
# 
studies 
 UC       
Colorectal 
cancer: men 
 1.80 1.04 3.12 0.0% 0.36 2 
Colorectal 
cancer: women 
 0.73 0.26 2.04 0.0% 0.59 2 
Cardiovascular 
disease: men 
 0.93 0.69 1.24 41% 0.13 6 
Cardiovascular 
disease: women 
 0.93 0.69 1.25 21% 0.28 6 
Pulmonary 
disease: men 
 1.13 0.59 2.17 46% 0.12 5 
Pulmonary 
disease: women 
 1.55 1.07 2.26 0.0% 0.87 4 
Nonalcoholic liver 
disease: men 
 NS      
Nonalcoholic liver 
disease: women 
 1.67 0.04 9.28 …. …. 1 
 CD       
Colorectal 
cancer: men 
 3.50 1.64 7.45 …. …. 1 
Colorectal 
cancer: women 
 NS      
Cardiovascular 
disease: men 
 0.87 0.61 1.25 0.0% 0.82 5 
Cardiovascular 
disease: women 
 1.22 0.70 2.11 53% 0.08 5 
Pulmonary 
disease: men 
 1.54 0.91 2.63 0.0% 0.62 5 
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Pulmonary 
disease: women 
 2.054 1.408 2.997 0.0% 0.56 5 
Nonalcoholic liver 
disease: men 
 NS      
Nonalcoholic liver 
disease: women 
 3.60 1.00 9.20 …. …. 1 
 UC 
Colorectal 
cancer 
      
North America  1.60 0.90 2.80 …. …. 1 
United Kingdom  NS      
North Europe  2.60 1.27 5.29 79.4
% 
0.01 3 
South Europe  2.31 0.87 6.09 54.7
% 
0.14 2 
Other countries  9.93 4.67 17.3 …. …. 1 
EC-IBD††  NS      
 UC 
Cardiovascular 
disease 
      
North America  0.76 0.52 1.13 65.9
% 
0.09 2 
United Kingdom  0.70 0.45 1.10 …. ….. 1 
North Europe  1.01 0.90 1.15 16.9
% 
0.31 4 
South Europe  0.72 0.56 0.93 0.0% 0.79 3 
Other countries  NS      
EC-IBD††  1.07 0.71 1.54 …. …. 1 
 UC 
Pulmonary 
disease 
      
North America  1.15 0.84 1.59 0.0% 0.56 2 
United Kingdom  0.80 0.36 1.60 …. …. 1 
North Europe  1.64 1.34 2.00 0.0% 0.57 5 
South Europe  0.18 0.00 1.10 …. …. 1 
Other countries  NS      
EC-IBD††  2.01 1.00 3.60 …. …. 1 
 UC 
Nonalcoholic 
liver disease 
      
North America  1.20 0.40 2.60 …. …. 1 
United Kingdom  NS      
North Europe  3.50 2.05 5.98 22.4
% 
0.28 3 
South Europe  0.50 0.03 3.00 …. … 1 
Other countries  NS      
EC-IBD††  NS      
 CD 
Colorectal 
cancer 
      
North America  1.90 0.90 3.70 …. … 1 
United Kingdom  NS      
North Europe  1.08 0.24 4.81 34.4
% 
0.22 2 
South Europe  3.86 0.86 17.20 0.0% 0.45 2 
Other countries  64.4 7.72 232.5
0 
…. … 1 
EC-IBD††  NS      
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 CD 
Cardiovascular 
disease 
      
North America  0.96 0.77 1.19 0.0% 0.41 2 
United Kingdom  0.80 0.50 1.38 …. …. 1 
North Europe  1.03 0.88 1.21 0.0% 0.78 4 
South Europe  0.65 0.24 1.41 …. …. 1 
Other countries  NS      
EC-IBD††  1.49 0.74 2.66 …. …. 1 
 CD 
Pulmonary 
disease 
      
North America  1.89 1.35 2.64 0.0% 0.94 2 
United Kingdom  0.90 0.42 2.06 …. …. 1 
North Europe  1.28 0.81 2.03 0.0% 0.50 4 
South Europe  NS      
Other countries  NS      
EC-IBD††  2.66 0.72 6.80 …. …. 1 
 CD 
Nonalcoholic 
liver disease 
      
North America  2.60 1.00 5.30 …. …. 1 
United Kingdom  NS      
North Europe  3.10 1.24 7.73 0.0% 0.36 2 
South Europe  NS      
Other countries  NS      
EC-IBD††  NS      
 UC 
Colorectal 
cancer 
      
Inception   2.85 1.59 4.69 …. …. 1 
Population   2.60 1.21 5.61 86.4
% 
0.00 5 
Single-center   NS      
Multi-center   3.46 1.58 6.57 …. …. 1 
 UC 
Cardiovascular 
disease 
      
Inception   1.00 0.82 1.23 49.4
% 
0.10 5 
Population   0.90 0.79 1.04 29.6
% 
0.24 4 
Single-center   0.65 0.26 1.34 …. …. 1 
Multi-center   0.76 0.56 1.02 0.0% 0.66 2 
 UC 
Pulmonary 
disease 
      
Inception   1.60 1.22 2.10 11.4
% 
0.34 5 
Population   1.49 1.24 1.80 0.0% 0.41 4 
Single-center   NS      
Multi-center   0.49 0.13 1.94 51.7
% 
0.15 2 
 UC 
Nonalcoholic 
liver disease 
      
Inception   4.80 2.07 9.45 …. …. 1 
Population   1.91 0.79 4.60 57.4 0.10 3 
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% 
Single-center   NS      
Multi-center   0.50 0.03 3.00 …. …. 1 
 CD 
Colorectal 
cancer 
      
Inception   0.30 0.01 1.67 …. …. 1 
Population   1.82 1.03 3.22 0.0% 0.97 3 
Single-center   5.40 0.60 19.00 …. …. 1 
Multi-center   64.40 7.72 232.5
0 
…. …. 1 
 CD 
Cardiovascular 
disease 
      
Inception   0.97 0.79 1.19 0.0% 0.60 5 
Population   1.04 0.88 1.22 0.0% 0.49 3 
Single-center   0.80 0.50 1.38 …. …. 1 
Multi-center   NS      
 CD 
Pulmonary 
disease 
      
Inception   1.67 1.11 2.49 0.0% 0.75 5 
Population   1.33 0.52 3.39 65.0
% 
0.09 2 
Single-center   0.90 0.42 2.06 …. …. 1 
Multi-center   NS      
 CD 
Nonalcoholic 
liver disease 
      
Inception   0.91 0.02 5.10 …. …. 1 
Population   2.99 1.59 5.62 0.0% 0.62 2 
Single-center   NS      
Multi-center   NS      
 UC 
Colorectal 
cancer 
      
Decade 2000s  NS      
Decade 1990s  1.53 0.92 2.53 0.0% 0.71 2 
Decade 1980s  3.30 0.94 11.67 87.5
% 
0.00 3 
Decade 1970s  3.76 2.50 5.66 46.7
% 
0.17 2 
Decade 1960s  NS      
Decade 1950s  NS      
 UC 
Cardiovascular 
disease 
      
Decade 2000s  NS      
Decade 1990s  0.92 0.74 1.13 34.5
% 
0.21 4 
Decade 1980s  0.94 0.73 1.20 18.2
% 
0.29 3 
Decade 1970s  0.89 0.69 1.16 74.1
% 
0.02 3 
Decade 1960s  NS      
Decade 1950s  0.70 0.45 1.10 …. …. 1 
 UC 
Pulmonary 
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disease 
Decade 2000s  NS      
Decade 1990s  1.33 0.84 2.11 36.1
% 
0.21 3 
Decade 1980s  0.67 0.08 5.69 80.5
% 
0.02 2 
Decade 1970s  1.60 1.25 2.03 0.0% 0.41 4 
Decade 1960s  NS      
Decade 1950s  0.80 0.36 1.60 …. …. 1 
 UC 
Nonalcoholic 
liver disease 
      
Decade 2000s  NS      
Decade 1990s  1.20 0.40 2.60 …. …. 1 
Decade 1980s  0.70 0.15 3.20 0.0% 0.72 2 
Decade 1970s  3.82 2.46 5.93 0.0% 0.47 2 
Decade 1960s  NS      
Decade 1950s  NS      
 CD 
Colorectal 
cancer 
      
Decade 2000s  NS      
Decade 1990s  1.87 0.94 3.72 0.0% 0.85 2 
Decade 1980s  18.73 1.65 212.5
9 
75.1
% 
0.05 2 
Decade 1970s  1.08 0.24 4.81 34.4
% 
0.22 2 
Decade 1960s  NS      
Decade 1950s  NS      
 CD 
Cardiovascular 
disease 
      
Decade 2000s  NS      
Decade 1990s  1.03 0.84 1.28 0.0% 0.47 4 
Decade 1980s  0.90 0.50 1.50 ….. ….. 1 
Decade 1970s  1.01 0.85 1.19 0.0% 0.42 3 
Decade 1960s  0.80 0.50 1.38  ….. 1 
Decade 1950s  NS      
 CD 
Pulmonary 
disease 
      
Decade 2000s  NS      
Decade 1990s  1.91 1.35 2.69 0.0% 0.50 3 
Decade 1980s  1.38 0.59 2.71 ….. …. 1 
Decade 1970s  1.45 0.88 2.41 8.1% 0.34 3 
Decade 1960s  0.90 0.42 2.06  ….. 1 
Decade 1950s  NS      
 CD 
Nonalcoholic 
liver disease 
      
Decade 2000s  NS      
Decade 1990s  2.60 1.00 5.30 …. …. 1 
Decade 1980s  NS      
Decade 1970s  3.10 1.24 7.73 0.0% 0.36 2 
Decade 1960s  NS      
Decade 1950s  NS      
*NS—no studies; EC-IBD--European Collaborative Study Group of Inflammatory Bowel Disease 
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†Decade refers to decade of the middle year of patient observation in study 
 
 
Table 2.6:  Table of included diagnoses (ICD codes) for cause-specific mortality 
Study Colorectal 
cancer 
Cardiovascular 
disease 
Pulmonary 
disease 
Nonalcoholic 
liver disease 
Romberg-Camps 
(2010)81 
NA ICD10: 099-118 ICD10: 122–134 NA 
Solberg (2009)83 NA NA NA NA 
Hutfless (2007)84 ICD9: 153–154 
ICD10: C18–C20 
ICD9: 390-459 
ICD10: I00 –I99 
ICD9: 466 –519 
ICD10: J02–J98 
ICD9: 571 
ICD10: K70–
K76 
Canavan (2007)85 NA NA NA NA 
Park (2007)86 NA NA NA NA 
Jess (2007)87 NA NA NA NA 
Hoie (2007)88 NA ICD10: 099-118 ICD10: 122-134 NA 
Delaunoit (2006)89 NR NA NA NA 
Jess (2006)90 NA ICD9: 390–459 ICD9: 460–519 NA 
Wolters (2006)91 NA NR NR NA 
Masala (2004)92 ICD9: 153–154 ICD9: 390–459 NA NA 
Card (2003)93 NA NA NA NA 
Winther (2003)94 ICD10: C18-
C20.9 
ICD10: I00-I52.9 ICD10: J00-99 ICD10: K71-
77.9 
Uno (2003)95 NR NA NA NA 
Jess (2002)96 NA ICD10: I00-25, 
I27, I30-52 
ICD10: J00-99 NA 
Viscido (2001)80 ICD9: 153-154 ICD9: 390-459 ICD9: 460~519 ICD9: I 55 
Farrokhyar 
(2001)97 
NA NA NA NA 
Katoh (2000)98 NA NA NA NA 
Ishibashi (1999)99 ICD9: 153-154 NA NA NA 
Saro (1999)100 NA NA NA NA 
Palli (1998)101 ICD9: 153-154 ICD9: 390–459 ICD9: 460–519 NA 
Davoli (1997)102 NA ICD9: 390-459 NA NA 
Persson (1996)103 ICD9: 153–154 ICD9: 390–458 ICD9: 460–519 ICD9: (570–573 
excluding 571.0 
Cottone (1996)104 NR NA NA NA 
Stewenius 
(1995)105 
NA NA NR NA 
Probert (1993)106 NA NA NA NA 
Ekbom (1992)107 ICD7: 153–154 
ICD8: 153–154 
ICD7: 400-468 
ICD8: 390-458 
ICD7: 470-527 
ICD8: 480-519 
ICD7: 580-583 
(excluding 
5811) 
ICD8: 570-573 
(excluding 
5170) 
Probert (1992)108 NA NA NR NA 
Weterman 
(1990)109 
NA NA NR NA 
Gyde (1982)110 NA ICD7: 400-468 ICD7: 470-527 NA 
Eason (1982)111 NR NR NA NA 
Prior (1981)112 NA ICD7: 400-468 ICD7: 470-527 NA 
Ritchie (1978)113 NA NA NA NA 
Gilat (1976)114 NA NA NA NA 
Iversen (1968)115 NA NA NA NA 
NA: Not Applicable; NR:  Not Reported 
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Publication Bias 
 There was no evidence of publication bias for all-cause mortality or cause-
specific mortality for UC or CD (p>0.09 for all tests).   
Discussion: 
 The present meta-analysis shows a small increase in all-cause mortality for both 
UC and CD.  Cause-specific analysis reveals significantly increased mortality from CRC, 
pulmonary disease and nonalcoholic liver disease for UC; and from pulmonary and 
nonalcoholic liver disease for CD.  Cardiovascular-related mortality was not elevated for 
either UC or CD, which is congruent with prior meta-analysis72.   
We examined geographic region, time period and study design as potential sources of 
heterogeneity, but none entirely explained the observed heterogeneity among all-cause 
mortality.   
 This is the first meta-analysis to conclude that patients with UC have an 
increased mortality rate relative to the general population.  We observed this in the 
overall analysis of all-cause mortality, in population-based studies, in population plus 
inception cohort studies, but not in inception cohort studies alone.  A prior meta-analysis 
of inception cohort studies by Jess et al also did not observe a significantly increased 
mortality rate relative to the general population.73  Of note, our meta-analysis included 
four new inception cohort studies not included by Jess et al.81,83,87,97  However, we also 
categorized five studies in the Jess meta-analysis as population-based but not inception 
cohorts because it was not specifically stated that patients received their initial IBD 
diagnosis during their time within the cohort or the study did not explicating state it was 
an inception-cohort study.92,94,105-107,111  Additionally, we excluded abstracts from our 
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analysis while there was one abstract included in the Jess meta-analysis.  These 
conservative efforts in study inclusion and classification may have contributed to the 
slightly different results.  However, importantly, the summary SMRs for inception and 
population-based studies were similar in magnitude (UC inception 1.08, population 1.32; 
CD inception 1.34, population-based 1.39) and as expected combining inception cohorts 
and population-based studies yielded similar results (UC 1.17 (95% CI 1.04-1.32); CD 
1.37 (95% CI 1.22-1.53)).   
 Inception cohorts by definition include all follow-up time in the early stages of 
disease but may not be able to follow patients for a sufficiently long time period in the 
later years of disease to fully assess long-term risk of mortality, in particular cancer-
related mortality and mortality related to long-term complications of IBD.  In contrast, 
non-inception population-based cohorts include some patients in the early stages of 
disease and others with late stage disease.  Thus inception cohorts are better suited to 
capture early mortality as their observation time occurs at the onset of disease; while 
population-based studies are better suited to capture late mortality given their 
observation time occurs at any stage of disease.  It has been suggested that all-cause 
mortality from UC peaks within the first year of diagnosis.1,116-118  If this were the case, 
inception cohort studies would be expected to observe higher all-cause mortality rates 
than population-based studies.  Unfortunately, in our study, we were unable to assess 
whether the relative risk of mortality varied by years after IBD diagnosis.   
We used cumulative meta-analysis and meta-regression to examine trends in 
relative mortality rates over time.  We hypothesized that, over time, the overall mortality 
rates for IBD patients would move towards 1.0.  For UC, this was evident examining the 
earliest studies with continued improvement over the range of the cumulative meta-
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analysis, and from our analysis excluding the two earliest studies where the summary 
SMR is not significantly elevated.  This may be due to improved surgical options for UC 
over time.  However, for CD, overall mortality has not shown a significant change over 
time.  Given that there were no studies meeting our inclusion criteria documenting 
mortality rates in the 2000’s, it remains possible that there has been a decrease in 
mortality due to improved medical therapy in recent years.  Given the shift in treatment 
patterns including more frequent use of thiopurines, methotrexate and anti-TNFα 
therapies, this is an important question for future research.46,119    
This current study suggests multiple potential sources of elevated mortality 
including CRC, and pulmonary- and hepatic-disease, some of which may be preventable 
deaths (Table 3).  Prior meta-analyses and reviews of these studies have found elevated 
pulmonary-related mortality in IBD, with observed causes including COPD (CD) and 
pneumonia (UC).73,74,120 Our current meta-analysis evaluated a greater number of 
studies and found similarly elevated pulmonary-related relative mortality for both UC and 
CD.  It is plausible that similar causes drove our all cause mortality findings as well, 
raising potential avenues for intervention including increase use of smoking cessation 
counseling and pneumonia and influenza vaccines.   
 Similarly to Jess et al, we observed an elevated relative risk of death for non-
alcoholic liver disease mortality in UC.73  It has long been recognized that patients with 
UC are at an increased risk of primary sclerosing cholangitis (PSC) and its 
complications.121  We also found that CD patients had a slightly higher relative risk of 
dying from liver disease.  This finding raises the question of whether PSC is more 
aggressive in CD, under recognized in CD,122 or if another form of liver disease is driving 
this increased mortality, such as fatty liver disease.  These findings suggest potential 
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utility of monitoring in IBD patients for liver disease, although this has never been proven 
in clinical trials.   
Death from CRC-related mortality has long been described in IBD, although the 
two most recent meta-analyses showed a non-significant or marginally significantly 
increased CRC-related mortality in CD and UC, respectively.73,74  Our current meta-
analysis found an elevated risk of relative mortality for CRC in UC and a trend towards 
an elevated risk of CD.  Our inclusion of single and multi-center studies could have 
contributed to this.  In our stratified analysis for UC, all study types yielded elevated 
relative risks of mortality for CRC, although multi-center studies did contribute the 
highest risk (see Table 5).  In contrast, for CD, there was an elevated relative risk of 
mortality for the population-based studies and the two referral-based studies, but not for 
the inception-based study (see Table 5).  It is possible, as discussed above, that 
inception cohorts were not able to follow patients for a sufficiently long time period to 
capture long-term mortality such as colorectal cancer. 
It is plausible that the relative risk of CRC mortality is decreasing over time, as 
access to care and screening for CRC has increased.123  Although we were 
underpowered to make strong correlations, there appeared to be a trend towards 
decreased relative mortality over decade time in UC, although not in CD (see Table 5).  
This could reflect greater awareness of the need for CRC surveillance in UC, although 
recent evidence argues against this.124  Alternatively, there could be more frequent use 
of chemopreventative agents such as mesalamine in UC than in CD, albeit these 
chemopreventative effects have not been definitively proven.125  Finally, reduction in 
CRC-related relative mortality among IBD patients would need to exceed that observed 
in the general population for this to be evident as a relative risk reduction.  Increased 
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CRC screening in the general population could obscure improvements in CRC-related 
mortality among patients with IBD when using relative risk estimates as the summary 
measure. 
There are several limitations in this study.  In some cases, cause of death was 
ascertained from death certificates and therefore subject to potential misclassification 
bias.  As described above, there is the potential for misclassification of inception versus 
population cohort studies.  SMRs are only age- and sex-adjusted; therefore other 
characteristics of the study populations may have contributed to heterogeneity.  For 
example, we were unable to assess whether current or former smoking contributed to 
excess mortality.  Disease severity was not assessed in the included studies and 
therefore we were unable to assess heterogeneity in overall mortality by disease 
severity.  Finally, we could not determine whether the attributable risk of death due to 
IBD differs by age.  These all remain important questions. 
In summary, this is the largest and most comprehensive meta-analysis 
evaluating all-cause and cause-specific mortality in IBD to date.  This is the first meta-
analysis to observe an elevated overall relative mortality for patients with UC.  We found 
little evidence of significant differences in all-cause relative mortality summary estimates 
for population- versus inception-based studies for either UC or CD.  We also confirmed 
the previously reported increased all-cause relative mortality for patients with CD.  
Additionally, we have found statistically increased colorectal-, pulmonary- and non-
alcoholic liver disease-related relative mortality for UC; and a statistically increased 
pulmonary- and non-alcoholic liver disease-related relative mortality for CD.  
Cardiovascular-related relative mortality was not elevated for either UC or CD.  Further 
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work evaluating specific etiologies of these cause-specific mortalities is likely to be 
illuminating.   
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Abstract: 
Background & Aims: 
There is a need for a simple, non-invasive patient-driven disease assessment instrument 
to facilitate clinical research in ulcerative colitis (UC).  Therefore, we sought to determine 
the reliability of a simple two-item index that does not require physician contact, 
knowledge of extraintestinal manifestations, endoscopy, stool or blood tests to measure 
disease activity. 
Methods: 
A cross-sectional study was conducted to assess the correlation of the 6-Point Mayo 
score with the Simple Clinical Colitis Activity Index (SCCAI) and a single Likert-scale of 
patient-defined disease activity.  Spearman’s correlation, sensitivity, specificity and area 
under the receiver-operator curves (ROC) were calculated.  Subgroup analysis was 
conducted in patients with more severe UC, defined as current or prior exposure to 
immunosuppressant therapy.  A separate validation study was conducted in which 
additional analysis was performed evaluating performance characteristics in left-sided 
and pancolitis UC. 
Results: 
The 6-Point Mayo score was strongly correlated with the SCCAI (rho = 0.71, p<0.0001) 
and with patient-driven reported disease activity (rho = 0.65, p<0.0001).  The SCCAI 
was similarly correlated with patient-driven reported disease activity (rho = 0.66, 
p<0.0001).  Using a cut point of 1.5, the 6-Point Mayo score had a sensitivity of 83% and 
a specificity of 72% for patient-defined remission; and a sensitivity of 89% and a 
specificity of 67% for SCCAI-defined remission (score <2.5).  The 6-Point Mayo score 
and SCCAI had similar accuracy of predicting patient-defined remission, with an area 
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under the ROC curve of 0.84 and 0.87, respectively.  Addition of the SCCAI urgency and 
general well-being questions to the 6-Point Mayo resulted in an area under the ROC 
curve of 0.90.  Similar findings were seen in the populations of patients with current or 
prior exposure to immunosuppressant therapy; however, addition of the SSCAI urgency 
and general well-being in this population did not significantly improve the discriminative 
ability of the index.  In the external validation study, strong correlations were again seen 
between the 6-Point Mayo score and SCCAI (rho = 0.73, p <0.0001) and patient-driven 
reported disease activity (rho = 0.63; p < 0.0001); and between the SCCAI and patient-
driven reported disease activity (rho = 0.73; p <0.0001).  These significant correlations 
remained when examining patients with left-sided colitis and pan-colitis UC.  In the full 
validation cohort, the 6-Point Mayo score had a sensitivity of 90% and a specificity of 
65% for patient-defined remission; and a sensitivity of 95% and specificity of 79% for 
SCCAI-defined remission.  Both the 6-Point Mayo score and SCCAI had similar 
accuracy of predicting patient-defined remission, with an area under the ROC curve of 
0.80 and 0.87, respectively.   Addition of both the SCCAI general well-being and urgency 
components significantly improved the 6-Point Mayo ability to predict patient-defined 
remission.  None of the clinical activity indices examined (the 6-Point Mayo, the SCCAI 
or a single Likert-scale of patient-defined disease activity) had good correlations with the 
UC Endoscopic Index of Severity (UCEIS). 
Conclusions: 
The 6-Point Mayo score correlates strongly with the SCCAI and with patient-reported 
disease activity and represents a simple option for assessing disease activity in UC in 
clinical trials and observation studies without requiring direct physician contact.  The 
addition of information regarding urgency and general well-being improved the test 
operating characteristics. 
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Background: 
 Ulcerative colitis (UC) is a chronic relapsing inflammatory disease of the colon.  
Assessment of disease severity is useful in the conduct of clinical research related to 
UC.  Often disease activity needs to be assessed not only at study initiation but at 
repeated time points throughout the study.  Currently, no gold-standard for disease 
severity assessment in UC exists.  However, at least 14 disease activity indices have 
been developed, many of which include invasive testing, laboratory tests, and/or 
physician assessment that can make studies costly, difficult to implement and can deter 
patient enrollment, especially with repeated measurements.75  Therefore, there is a need 
for a simple, non-invasive patient-driven disease assessment instrument. 
 One disease severity index that does not require physician assessment, invasive 
testing or laboratory tests is the Simple Clinical Colitis Activity Index or SCCAI (Table 
3.1).126  This index includes six variables that were found to best predict the original 
Powell-Tuck classification of UC remission:  bowel frequency during the day and night, 
urgency of defecation, blood in the stool, general well-being and extra-colonic 
manifestations of UC.  The SCCAI has been shown to have robust discriminative and 
construct validity as well as test-retest reliability and responsiveness to change; and a 
score of < 2.5 points has been shown to correlate with Patient-Defined Remission.76,77  It 
has also been shown to correlate well with invasive indices of UC disease activity.127  
While the SCCAI is completely patient-driven, it includes some variables such as extra-
intestinal manifestations that may be ambiguous to patients and thus cause incorrect 
patient-reporting of current disease activity.  Additionally, the quantity of questions in the 
SCCAI can make it cumbersome in studies with repeated measurements. 
 The Mayo Score is the index most commonly used in clinical trials and consists 
of only four items:  stool frequency, rectal-bleeding, flexible sigmoidoscopic examination 
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and a physician global assessment (Table 3.1).128  A non-invasive 9-Point Mayo or 
Partial Mayo incorporates stool frequency, rectal bleeding and the physician’s global 
assessment.  The Partial Mayo has been found to correlate closely with the full Mayo 
score, and to independently have strong discriminative and construct validity and 
responsiveness to change in disease activity.77,78  However, this scoring system still 
requires face-to-face evaluation with a physician.  Therefore, a purely patient-driven 6-
Point Mayo has also been infrequently utilized.  Two prior studies have found that the 6-
Point Mayo correlates very well with the Partial and Full Mayo scores, and a cut-off of 
1.5 has been shown to correlate with patient-defined remission.78,79  However, no study 
has sought to correlate the 6-Point Mayo score with disease severity indices outside of 
the Mayo scoring system. Therefore, the aim of our study was to assess the correlation 
of the 6-Point Mayo score with the SCCAI and a single Likert-scale of patient defined 
disease activity (Table 3.1).  We also sought to evaluate correlations between the 6-
Point Mayo, the SCCAI and patient-defined disease activity in patients with more severe 
disease, as defined as current or prior exposure to immunosuppressant therapy.  To 
further confirm these findings, we conducted a validation study in a separate population 
of UC patients with defined disease distribution.   
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Materials and Methods 
Data for the initial study were acquired from a recently completed mailed 
questionnaire-based conjoint analysis study conducted at the University of Pennsylvania 
and Dartmouth-Hitchcock Medical Center. The purpose of this conjoint analysis study 
was to assess patient preferences for surgical versus medical therapy for a UC disease 
flare.  The study included patients ≥ 18 years old with an International Statistical 
Classification of Diseases (ICD)-9 code for UC (556.0-556.6 and 556.8-556.9), no 
concomitant ICD-9 code for Crohn’s disease (555.0-555.2, 555.9) and an outpatient 
gastroenterology clinic visit within the prior 24 months.  The survey included two 
separate questions asking participants if they had UC.  To be included in this substudy, 
50 
 
participants had to answer both questions in the affirmative and have no missing data for 
any of the disease severity questions that are described below. 
The survey instrument included all aspects of the SCCAI and the 6-Point Mayo 
score.  Illustrations and descriptions aimed at a 6-grade reading level were used to 
illustrate the extra-intestinal manifestation questions in the SCCAI to limit patient 
confusion or lack of understanding of the medical terminology in the index.  Furthermore, 
we included a single patient-driven disease activity question that read, “Please check 
what you would describe as your ulcerative colitis activity over the past 3 days.”  There 
were six possible responses to this question (Table 3.1). 
The validation study utilized the same SCCAI and 6-Point Mayo indices 
questions (including the illustrations and descriptions) as well as the single patient-driven 
disease activity question utilized in the initial study.  This study was administered to 
consecutively enrolled clinic patients in separate prospective cohort study at the 
University of Pennsylvania (IBD Immunology Initiative or I3 study).  All patients were  ≥ 
18 years old with an ICD-9 code for UC (556.0-556.6 and 556.8-556.9) confirmed by a 
gastroenterologist and verified by review of the patient’s electronic medical record.  
Patients also had to be capable of providing informed consent.  Review of the patient’s 
electronic medical record also served to confirm disease extent (left-sided colitis versus 
extensive colitis). 
Descriptive statistics were used to describe patients included in the study.  
Continuous variables are reported as medians; and categorical variables as proportions.  
Correlations were measured using Spearman correlation coefficients (rho). To assess 
sensitivity and specificity for the SCCAI and the 6-point Mayo we used the patient-driven 
disease activity question as the gold standard.  Clinical remission was defined as a self-
assessment of perfect or very good (minimal disease activity).  Receiver operating 
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characteristic (ROC) curves were generated and area under the ROC curves (AUC) for 
different disease indices were computed.  Logistic regression modeling and chi-square 
tests were used to compare AUC from different ROC curves.  SAS v.9.1 was used for 
data management and analysis.  The study design was approved by the Institution 
Review Boards at both the University of Pennsylvania and Dartmouth Hitchcock Medical 
Center 
Results 
Initial Survey 
 The survey for the 
initial study was mailed to 
775 UC patients and 
responses were received 
from 442 patients (57% 
response rate).  We had 
limited information on non-
responders, but men were 
less likely to respond (data 
not shown).  After applying 
the exclusion criteria, 282 
participants were included in 
the final analysis (Figure 
3.1). 
 Baseline 
demographics of the initial 
survey population are shown in Table 3.2.  The majority of respondents were female and 
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Caucasian with a mean age of 47 years.  Most had UC for more than one year with a 
mean duration of disease of 13 years.  29% stated they were having a current flare of 
their UC.  The majority of respondents were on or had been on some form of 5-ASA 
therapy for their UC.  The majority also had prior exposure to corticosteroids, although 
only 11% were currently taking corticosteroids.  Approximately one-third of respondents 
were currently on some form of immunosuppressant therapy (including thiopurine, 
cyclosporine, methotrexate or anti-TNF therapies) and an additional 20% had prior 
exposure to immunosuppressant therapy for their UC (Table 3.2). 
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SCCAI, 6-Point Mayo and Patient Assessment of Disease Activity 
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 The results of the disease severity assessments for the full survey population are 
shown in Table 3.3.  63% of the surveyed population were in a remission defined by the 
6-point Mayo or patient-driven activity question.  Notably, however, only 53% were in a 
remission defined by the SCCAI.  Among the 152 patients who had prior or current 
exposure to immunosuppressant therapy, there were slightly higher SCCAI mean and 
median scores; and overall, 4% fewer patients were in remission across each of the 
indices.  Again, a fewer percentage of patients with prior or current exposure to 
immunosuppressant therapy were considered to be in a remission by the SCCAI (49%) 
compared to either the 6-point Mayo (59%) or patient-driven disease activity question 
(59%). 
 
 Additional analysis was therefore conducted to explore why remission rates were 
lower with the SCCAI than with the 6-Point Mayo (Figure 3.2A) or patient-driven disease 
activity (Figure 3.2B).  In patients in a remission defined by the 6-Point Mayo score, 
three SCCAI questions appeared to be responsible for the discrepancy between the 6-
Point Mayo and the SCCAI, with over 50% of those with active disease (as defined by 
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the SCCAI) answering in the affirmative to the questions:  urgency, general-well being 
and presence/absence of arthritis (Figure 3.2A).  Similar results were seen when using 
the patient-driven disease activity question to define remission (Figure 3.2B).   
 
Correlation of patient-driven disease assessment, SCCAI and 6-Point Mayo 
 In the overall population, the 6-Point Mayo score was strongly correlated with the 
SCCAI, with a spearman correlation coefficient (rho) of 0.71 (p < 0.0001).  It was also 
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strongly correlated with the patient-driven disease activity question (rho = 0.65, p < 
0.0001).  A similarly significant correlation was seen with the SCCAI and the single 
patient-driven disease activity question with a spearman correlation coefficient of 0.66 (p 
< 0.0001).  When examining those patients with current or prior immunosuppressant 
exposure, the correlations were similarly strong:  6-Point Mayo and SCCAI rho = 0.73 (p 
< 0.0001); 6-Point Mayo and patient-driven question rho = 0.67 (p < 0.0001); and SCCAI 
and patient-driven question rho = 0.66 (p < 0.0001). 
Sensitivity, Specificity and ROC curves to Identify Patient-Defined Remission 
 Using a cut point of 1.5, the 6-Point Mayo remission score had a sensitivity of 
83% and a specificity of 72% for patient-defined remission; and a sensitivity of 89% and 
specificity of 67% for SCCAI remission defined as a score of < 2.5.  The SCCAI had a 
sensitivity of 76% and a specificity of 87% for patient-defined remission.  In patients with 
current or past immunosuppressant therapy exposure, the 6-Point Mayo remission score 
had a sensitivity of 82% and specificity of 73% for patient defined remission; and a 
sensitivity of 91% and specificity of 71% for SCCAI remission. The SCCAI had a 
sensitivity of 73% and a specificity of 86% for patient-defined remission. 
 We defined remission using a single patient-driven disease activity question as 
perfect or very good under the assumption that patients would be unlikely to seek 
additional therapy if they considered themselves to have very good control of their 
disease.  However, we repeated the assessment of the sensitivity and specificity of the 
6-Point Mayo and SCCAI defining remission as only those who answered their disease 
activity as “perfect.”  This resulted in a lower specificity for both scoring systems: 6-Point 
Mayo sensitivity 89% and specificity 50%; SCCAI sensitivity 83% and specificity 61%. 
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 The ROC curves in 
the total population for the 
SCCAI and the 6-Point 
Mayo predicting patient-
defined remission are 
shown in Figure 3.3A and 
Figure 3.3B.  The SCCAI 
area under the curve was 
0.87 and the 6-Point Mayo 
area under the curve was 
0.84 in the full population 
(Figure 3.3A).  In patients 
exposed to 
immunosuppressant 
therapy, the ROC curves 
showed a similar nearly-
equivalent area under the 
curve for SCCAI and the 6-
Point Mayo with an area 
under the curve of 0.86 
and 0.85, respectively 
(Figure 3.3B). 
 Additional analysis 
was conducted to evaluate if adding any of the SCCAI components (utilizing their 
original SCCAI scaling) to the 6-Point Mayo improved the accuracy of predicting patient-
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defined disease remission (Table 3.4).  Two of the SCCAI components, urgency and 
general well-being, significantly increased the AUC when added to the 6-Point Mayo 
score (p=0.04 and p=0.0008, respectively).  When both components were added to the 
6-Point Mayo score, the resulting ROC area under the curve was 0.90, which was 
significantly greater than the area under the curve for the 6-Point Mayo score alone 
(p=0.0002).  Sequential addition of both urgency and general well-being was also 
performed:  the addition of the SCCAI general well-being to the 6-Point Mayo already 
containing the SCCAI urgency question resulted in a significant improvement in ROC 
area under the curve (0.87 vs. 0.90, p=0.005); however, the addition of the SCCAI 
urgency to the 6-Point Mayo already containing the SCCAI general well-being did not 
reach statistical significance (0.89 vs. 0.90, p=0.16).  Similar analysis was conducted 
looking at those patients exposed to immunosuppressant therapy; however, in this 
cohort, no SCCAI component reached a significantly improved AUC when added to the 
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6-Point Mayo score (Table 3.4).
  
Validation Study 
 In the prospective I3 cohort from, 112 consecutive UC patients were consented.  
Of these, 61 patients had physician-identified pancolitis (47 patients) or left-sided colitis 
(14 patients) confirmed by the patient’s electronic medical record and completed the 
disease severity indices without missing data.  These 61 patients were included in the 
validation study.  Baseline demographics of this population were not significantly 
different from the initial study population; however, a larger percentage of the validation 
population was currently on immunosuppressant therapy (Table 3.5).   
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SCCAI, 6-Point Mayo and Patient Assessment of Disease Activity 
 The results of the disease severity assessments for the validation survey 
population are shown in Table 3.6.  The percentage of patients in the total validation 
population in a remission was comparable by any of the three disease activity 
measurements; however, when comparing patients with pan-colitis versus left-sided 
colitis, a greater percentage of patients with left-sided colitis were in a remission. 
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Correlation of patient-driven assessment, SCCAI and 6-Point Mayo 
 In the validation population, the 6-Point Mayo was again strongly correlated with 
the SCCAI (rho = 0.73, p <0.0001) and the patient-driven disease activity question (rho = 
0.63, p < 0.0001).  A significant correlation was also seen with the SCCAI and the single 
patient-driven disease activity question (rho = 0.73, p<0.0001).  When examining pan-
colitis and left-sided colitis subsets of the validation study, the correlations were similarly 
strong.  In patients with pan-colitis, the correlations were rho = 0.75, p < 0.0001 (6-Point 
Mayo and SCCAI); rho = 0.61, p < 0.0001 (6-Point Mayo and single patient-driven 
disease activity question); and rho = 0.70, p < 0.0001 (SCCAI and single patient-driven 
disease activity question).  In patients with left-sided colitis, the correlations were rho = 
0.64, p < 0.0131 (6-Point Mayo and SCCAI); rho = 0.71, p < 0.0062 (6-Point Mayo and 
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single patient-driven disease activity question); and rho = 0.65, p < 0.0168 (SCCAI and 
single patient-driven disease activity question).   
Sensitivity, Specificity and ROC curves to Identify Patient-Defined Remission 
 In the validation study, the 6-Point Mayo remission score (<1.5) had a sensitivity 
of 90% and a specificity of 65% for patient-defined remission; and a sensitivity of 95% 
and specificity of 79% for SCCAI remission defined as a score of < 2.5.  The SCCAI had 
a sensitivity of 85% and a specificity of 65% for patient-defined remission.  The ROC 
curves in the validation population for the SCCAI and the 6-Point Mayo predicting 
patient-defined remission are shown in Figure 3.4.  The SCCAI area under the curve 
was 0.87 and the 6-Point Mayo area under the curve was 0.80.   
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Additional analysis was performed to assess if addition of individual components of the 
SCCAI to the 6-Point Mayo increased the accuracy of predicting patient-defined 
remission.  Notably, only one patient responded affirmatively to any of the extra-
intestinal manifestation components of the SCCAI; therefore, ROC comparisons adding 
these components could not be assessed.  In the validation cohort, no component of the 
SCCAI contributed significantly to improving the accuracy of the 6-Point Mayo in 
predicting patient-defined remission.  Based on the findings in the initial study cohort, 
additional analysis was run adding both the SCCAI urgency and general well-being 
64 
 
components to the 6-Point Mayo score (Table 3.7).  The resulting ROC area under the 
curve was 0.89, which just reached statistical significance compared to the area under 
the curve with the 6-Point Mayo alone (p=0.05).  Sequential addition of both urgency and 
well-being was also performed and not found to be significant (p=0.09 for addition of 
SCCAI general well-being to 6-Point Mayo already containing SCCAI urgency; and 
p=0.37 for addition of SCCAI urgency to 6-Point Mayo already containing SCCAI general 
well-being). 
 
Ulcerative Colitis Endoscopic Index of Severity 
Of the 61 patients in the validation study, 36 had a colonoscopy performed.  
Three of the patients had an incomplete colonoscopy performed either due to a stricture 
or disease severity; these three patients were removed from the analysis.  The 
remaining 33 patients had a complete colonoscopy that was retrospectively reviewed by 
an external gastroenterologist and scored according to the Ulcerative Colitis Endoscopic 
Index of Severity (UCEIS).129,130  Correlations between the clinical disease activity 
indices and the UCEIS were overall poor:  rho = 0.11, p = 0.54 (SCCAI and UCIS); rho = 
0.18, p = 0.31 (6-Point Mayo and UCEIS); and rho = 0.33, p = 0.06 (single patient-driven 
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disease activity question and UCEIS).  The SCCAI area under the curve was 0.62 and 
the 6-Point Mayo area under the curve was 0.59 (Figure 3.5). 
 
Discussion: 
 In this study, we have found and validated that the 6-Point Mayo score correlated 
strongly with the SCCAI and patient-reported disease activity, has a similar sensitivity 
and specificity as the SCCAI for patient-reported remission, and performs equally well in 
patients with more advanced disease (as defined by immunosuppressant drug 
exposure) as well as patients with varying UC disease extent (left-sided colitis versus 
pan-colitis).  Prior studies have shown that the 6-Point Mayo score correlates well with 
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patient-driven disease activity as well as both the Partial- and Full-Mayo scores.78,79  Our 
study is the first to correlate and validate the 6-Point Mayo with disease activity indices 
outside of the Mayo scoring system, and in patients on immunosuppression as well as 
patients with varying extent of UC.  Furthermore, the 6-Point Mayo score avoided the 
use of cumbersome and potentially confusing questions regarding extra-intestinal 
manifestations of the IBD, and thus represents a simple, efficient and effective non-
invasive disease severity measurement.   We have also shown that addition of one or 
two questions from the SCCAI may improve prediction of the 6-Point Mayo score with 
patient-defined disease activity with minimal additional burden to patients or 
researchers. 
In our initial study, patient-reported symptoms of urgency and general well-being, 
as collected by the SCCAI, led to discrepancies between a SCCAI-defined remission 
and a patient-defined remission.  As these questions are not asked in the 6-Point Mayo, 
discrepancies between remission as defined in the scoring systems can be expected.  It 
is possible that there may be points of confusion by the patients regarding each 
individual question and how it relates to their UC activity:  urgency in the prior three days 
can be an important symptom of UC-disease; but it may also reflect irritable bowel 
syndrome.  General well-being can be affected by many factors outside of UC disease 
activity.  We also conducted additional analysis adding back these questions to the 6-
Point Mayo and found that they do increase the accuracy of the 6-Point Mayo predicting 
patient-defined remission.  Based on sequential assessment, the addition of general 
well-being appears to be sufficient, and may represent a very simple addition to the 6-
Point Mayo.   
The extra-intestinal manifestation questions in the SCCAI, specifically arthritis 
and uveitis, also led to discrepancies between SCCAI-defined remission and a patient-
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defined remission in the initial study.  Both arthritis and uveitis are difficult to describe to 
patients, and without direct physician assessment can be easily mistaken with non-IBD 
related symptoms such as osteoarthritis or allergic conjunctivitis.  This illustrates a 
greater potential difficulty in eliciting the extra-intestinal IBD disease activity without 
direct physician contact.  For example, in our initial study population, a high percentage 
of respondents stated they had uveitis (a relatively rare extra-intestinal complication of 
IBD) in the past 3 days.  Despite these differences, the c-statistic for both scoring 
systems was very similar, indicating that overall, the remaining questions of stool 
frequency and bleeding accounted for much of the discriminative function in both 
indices.  Furthermore, analysis adding back these extra-intestinal manifestations to the 
6-Point Mayo did not result in improvements in the predictive ability of the scoring 
system, implying that these extra variables may be unnecessary in assessing active 
versus inactive disease. 
 Our validation study confirmed the correlation of the 6-Point Mayo score with the 
SCCAI and patient-defined disease remission.  It is also the first study to validate the 
performance of the 6-Point Mayo score in both disease severity as well as UC disease 
extent, confirming the utility of the 6-Point Mayo across a broad range of clinical 
populations.  Notably, in our validation population, while we did not find that the single 
addition of the SCCAI urgency or general well-being improved the accuracy of the 6-
Point Mayo in predicting patient-defined remission, the addition of both components did 
improve the 6-Point Mayo score accuracy.  It is possible that the validation study was 
simply underpowered to detect smaller differences at the individual component level, 
and certainly additional analysis exploring this should be performed.   
Additionally, in our validation study, we did not find the high reported rates of 
extra-intestinal manifestations that we saw in our initial study.  This may be the result of 
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differences in the study populations themselves:  whereas the initial study was a mailed 
questionnaire, completed entirely by the patient outside of the clinical setting, the 
validation study was collected in the clinical setting and during enrollment within a larger 
prospective study.  Unmeasured differences (recent exposure to a physician, willingness 
to enroll in a clinical study, etc) may have contributed to these variations, and stress the 
need for a simple, unambiguous patient-driven disease activity index. 
 There are potential limitations to our study.  Both our initial and validation studies 
were carried out using patients at one of two tertiary care centers and thus may not be 
generalizable to other clinical settings.  However, as such, they do represent a 
commonly-utilized UC population for clinical trials and therefore a population in whom a 
simple, patient-directed disease severity index would be most useful.  Additionally, the 
majority had extensive experience with UC, thus lending to improved validity of our 
findings.   
 Most of the patients surveyed in both studies were in a clinically-defined disease 
remission.  Despite this, we did have a broad range of UC disease severity, as 
evidenced by the high numbers of UC patients using immunosuppressant therapy as 
well as the variations in disease extent.  It is possible that the indices examined in this 
study would perform differently among patients with more severe or active disease.   
 The indices examined in this study were for clinical remission, specifically 
patient-defined remission, only.  We found that none of the clinical disease activity 
indices assessed (SCCAI, 6-Point Mayo or a single Likert-scale of patient-defined 
disease activity) correlated well with a purely endoscopic assessment of disease 
severity.  Prior work has shown a good correlation with the SCCAI and an invasive index 
of disease severity, the Powell-Tuck (or St. Mark’s) Index.127  However, the Powell-Tuck 
Index, like many of the scoring indices in UC, is a composite of clinical, biochemical, and 
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sigmoidoscopic evaluations of the patient, which may lend a greater correlation with a 
clinical index (such as the SCCAI or 6-Point Mayo) compared to a purely endoscopic 
evaluation.  Endoscopic and histologic disease activity measures have been correlated 
with important outcomes including colectomy, colorectal cancer and quality of life.75,131-134  
However, in many studies, invasive disease assessment may be infeasible or serve as a 
deterrent to patient enrollment.  Even in studies which employ invasive disease 
methods, more frequent follow-up measurements may be more easily obtained via mail, 
email, or phone, without direct physician contact.  Furthermore, patient-perceived 
assessment of disease activity is arguably paramount in assessing quality of life which, 
in turn, has effects on adherence to medical therapy.  In these settings, the utility of a 
simple patient-driven disease assessment tool can be appealing to researchers and 
patients alike. 
 In conclusion, we have demonstrated that the 6-Point Mayo score, comprised of 
only two questions regarding stool frequency and the presence of blood, was highly 
correlated with the SCCAI and performed comparably to the SCCAI in identifying 
patient-perceived clinical remission.  We have further shown that addition of either the 
SCCAI general well-being and/or urgency components increased the predictive value of 
the 6-Point Mayo with minimal additional survey burden.  Finally, we have validated our 
findings in a separate UC population, and further evaluated and validated our findings in 
patients of varying disease extent.  Therefore, the 6-Point Mayo score represents a 
simple and reproducible patient-driven disease severity index for use in observational 
studies or in clinical trials without direct physician assessment. 
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BACKGROUND:  Therapy options for mesalamine-refractory ulcerative colitis (UC) 
include immunosuppressive medications or surgery.  Chronic immunosuppressive 
therapy increases risks of infection and cancer, whereas surgery produces a permanent 
change in bowel function.  We sought to quantify the willingness of patients with UC to 
accept the risks of chronic immunosuppression to avoid colectomy. 
METHODS: We conducted a state-of-the-art discrete-choice experiment among 293 
patients with UC who were offered a choice of medication or surgical treatments with 
different features.  Random parameters logit was used to estimate patients’ willingness 
to accept tradeoffs among treatment features in selecting surgery vs medical treatment.   
RESULTS:  A desire to avoid surgery and the surgery type (ostomy versus J-pouch) 
influenced patients’ choices more than a specified range of 10 y mortality risks from 
lymphoma or infection, or disease activity (mild vs remission).  To avoid an ostomy, 
patients were willing to accept a greater than 5% 10-year risk of dying from lymphoma or 
infection from medical therapy, regardless of medication efficacy.  However, data on 
patients’ stated-choice indicated perceived equivalence between J-pouch surgery and 
incompletely effective medical therapy.  Patient characteristics and disease history 
influenced patients’ preferences regarding surgery vs medical therapy. 
CONCLUSIONS:  Patients with UC are willing to accept relatively high risks of fatal 
complications from medical therapy to avoid a permanent ostomy and to achieve durable 
clinical remission.   However, patients’ view J-pouch surgery, but not permanent 
ileostomy, as an acceptable therapy for refractory UC in which medical therapy is unable 
to induce a durable remission. 
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INTRODUCTION: 
 Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) that can be 
severely debilitating, and has no medical cure.  Historically, UC was treated with 
mesalamine and corticosteroids; and if these failed, surgical resection of the colon.  
Because UC is limited to the colon, surgery offers a theoretical “cure” and eliminates the 
risk of colon cancer.  The two most common operations performed are a total 
proctocolectomy with end ileostomy and restorative ileal pouch anal anastomosis 
(IPAA).  The former entails a permanent ileostomy while the latter avoids this but is 
associated with frequent bowel movements and the risk of fecal incontinence. 
 The demonstrated efficacy of thiopurine analogues and antibodies against tumor 
necrosis factor α has improved our ability to induce and maintain remission.  However, at 
least one-third of patients will fail to produce a durable remission.41,135,136  These patients 
will often be exposed to repeated or chronic corticosteroid therapy which is associated 
with increased morbidity and mortality.20,21,23  Furthermore, chronic immunosuppressant 
maintenance therapy risks serious and opportunitistic infections,21,26,137  and an 
increased the risk of certain cancers including lymphoma30,31 and hepatosplenic T-cell 
lymphoma.138,139      
If surgery for UC resulted in a completely normal quality of life, the choice 
between medical and surgical therapy would be obvious.  Because this is not the case, 
physicians and their patients are willing to accept risks of medical therapies, often with 
the presumption that the patient’s foremost desire is to avoid surgery.  However, for 
some patients this may not be the case; and in an era that places an increasing premium 
on patient autonomy and shared decision making, quantifying UC patients risk 
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preferences includes their voice in an increasingly complex decision process.  
Furthermore, quantifying patients’ risk threshold can help physicians, drug 
manufacturers and regulators when contemplating appropriate indications for existing 
and new medical therapies. Prior studies evaluating UC patients’ preferences have been 
few and employed methodologies that make numerous uncertain or inaccurate 
assumptions about patient preferences.50,61  In this study, we used an innovative patient-
preference methodology called discrete-choice experiment (DCE) to quantify the UC 
patients’ tolerance for life-threatening serious adverse events (SAEs) in exchange for 
specific treatment benefits.  We estimated the mean maximum acceptable risk (MAR) for 
SAEs associated with immunosuppressant therapy in UC that patients are willing to 
accept to avoid colectomy with ostomy, IPAA or IPAA complicated by fecal incontinence.  
We also evaluated how clinical characteristics affect tolerance for medical therapy risks 
in preference to surgery.   
MATERIALS AND METHODS: 
DCEs, also known as choice-format conjoint analysis, quantify strength of 
preferences for features of products, services, or health-care interventions and are 
increasingly being applied in the health sciences.67,140,141  Interventions, such as medical 
or surgical treatments, derive value from their specific attributes, features or outcomes 
including treatment efficacies and potential SAE risks.  Each of these attributes can 
occur at varying levels, such as remission rates or SAE incidence.  DCEs recognize that 
patients have preferences of varying strengths for different attributes and are willing to 
accept tradeoffs among various levels.  By systematically eliciting tradeoffs among 
constructed outcome combinations, DCEs generate choice data to quantify implicit 
decision weights indicating relative utility or satisfaction that patients have for both 
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individual attributes of a treatment (such as the specific risks and benefits) as well as the 
treatment as a whole.  Because DCEs measure the rate at which patients accept 
tradeoffs among different treatment attributes, it is possible to use these trade-off rates 
to scale a change in one attribute to equivalent units of another attribute. It is thus 
possible to calculate time equivalents, money equivalents, and risk equivalents of a 
given change in treatment options. In this study, we used estimated trade-off rates to 
calculate the MAR as an indication of patients’ willingness to accept medication-related 
SAE risks to avoid surgery.  
Survey Development 
 A DCE survey instrument was developed using best-practice methods142 to elicit 
patients’ willingness to accept tradeoffs among therapeutic options regarding medical 
and surgical interventions for UC. The survey instrument assessed respondents’ 
baseline demographics, current disease activity (using the Simple Clinical Colitis Activity 
Index (SCCAI) and 6-point Mayo score),79,126 medication use history and knowledge of 
colectomy surgery. Numeracy was assessed using test questions.   
For the DCE scenarios, attributes were determined from a literature review, IBD 
expert consultation, focused interviews with IBD patients and a pilot study in 127 UC 
patients.  On the basis of this information, a decision frame was developed in which 
respondents assume a moderate-to-severe UC flare and must select either a new 
medication or surgery as treatment for the flare (Table 4.1).  Medication treatment 
attributes included efficacy with levels of remission and incomplete response resulting in 
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mild disease activity for 10 years, described using text from the Mayo score.128      
 
Surgery was described as a one- or two-step process with a resultant permanent 
surgical remission.  A permanent ostomy (single stage operation) was described as 
having a surgical remission with no blood, abdominal pain, fatigue or interference with 
job/daily activities and having bowel movements through the ostomy.  Pictures of female 
and male patients with ostomy bags were shown.  Two-stage (IPAA) surgery was 
described as resulting in an average 5 bowel movements per day but otherwise having 
similar disease-activity symptoms as those having an ostomy.  Incontinence also was 
described.  All surgery was described as carrying a one-in-three chance of having 
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difficulty becoming pregnant for female patients.  Pilot testing indicated good 
understanding of the medical and surgical outcomes.   
 For non-surgical options, a 0.3% risk of dying from colon cancer within 10 years 
was included.143  Two SAEs were additionally considered.  The risk of dying from 
lymphoma was only associated with selection of medication therapy; the risk of dying 
from a serious infection was associated with both medication therapy and surgery.  
Colorectal cancer, lymphoma and serious infections were described using layman terms 
based in part on descriptions from the American Cancer Society patient information144.  
For each of the SAEs, hypothetical risk levels ranged from 0% to 5% for experiencing 
the event within the next 10 years.  Pretest interviews and pilot data indicated that this 
range yielded trade-off information required to quantify MAR. The 10-year time frame 
was determined to be appropriate during piloting and data collection/analysis from 
conceptual, methodological and patient-cognitive perspectives.  Pretests of the 
instrument found that 10 years allowed for magnification of annual risks to levels that 
could be described graphically and were sufficiently salient to induce tradeoffs among 
other attributes.   
To limit cognitive burden and numeracy concerns, all treatment benefits were 
described as certain and all treatment risks were described as known probabilities.  To 
avoid measurement error in preference elicitation and analysis, specific risk levels 
(rather than ranges) were presented in keeping with best practice methods.142  To further 
aid respondents understanding of quantitative risks, the SAE probabilities were 
presented in three ways:  graphically as a risk grid of shaded circles indicating the 
number of patients out of a full grid of 1000 circles who would die from the SAE; and 
numerically as fractions (counts out of 1000) and percentages (Figure 4.1).   
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 The DCE questions in the final survey instrument asked patients to choose 
between a medication resulting in either complete remission or incomplete remission 
(i.e. mild disease activity) for 10 years or surgical therapy for their UC disease flare.  
Figure 1 is an example of the DCE question format.  We used a variation of a commonly 
used algorithm in SAS to construct a D-efficent experimental design resulting in 48 pairs 
of treatment options.145-149  To reduce respondent burden, the trade-off scenarios were 
blocked into 6 sets of 8 questions.  Each participant was randomly assigned to receive 1 
of the 6 sets of questions.  Surveys were mailed using the Dillman method to maximize 
response rates.150    
Survey Validation 
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 The design of the DCE survey included tests for numeracy and an internal test 
for subject-level validity through logic testing.  To assess numeracy, subjects were 
shown a series of numerical examples of risk, presented as percentages, fractions and 
an illustrative risk grid, and subsequently tested on their understanding of these numeric 
concepts.  Logic testing was assessed to evaluate if respondents understood the 
question-choice format sufficiently to indicate a preference for a visibly better therapy 
through an additional trade-off scenario in which medication treatment dominated the 
surgical treatment for every attribute.  The model was tested to evaluate the statistical 
influence of respondents who failed one or both of these tests. 
Survey Sample 
 Patients were eligible if they were ≥ 18 years of age with an ICD-9 code for UC 
(556.0-556.6 and 556.8-556.9) and an outpatient gastroenterology clinic visit at 
participating institutions within the prior two years.  Patients with any ICD-9 code for 
Crohn’s disease (555.0-555.2, 555.9) were ineligible.  In the survey, patients were asked 
if they considered themselves to have UC; only respondents who further self-identified 
as having UC were included in the survey sample.  All patients received a small financial 
compensation for their time and effort.   
Statistical Analysis 
 In DCE studies, the pattern of choices by respondents observed reveals the 
implicit decision or preference weights respondents used to evaluate the hypothetical 
treatment tradeoffs.  Multivariate random-parameters logit was used to estimate 
preference weights for each attribute level while avoiding potential estimation bias in 
choice models from unobserved variation in preferences not accounted for by the 
variables in the model.151,152  Both a mean value and taste-distribution standard-deviation 
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parameter are estimated for each preference weight. A flexible correlation structure also 
accounts for within-sample correlation in the question sequence for each participant.   
Effects coding was used so that the mean effect of each attribute is normalized at 
zero instead of setting all the omitted categories to zero.  The omitted-category 
parameter is the negative sum of the included-category parameters for each attribute.  
This provides a parameter estimates for every attribute-level preference weight, avoids 
confounding the grand mean with marginal effects, and facilitates subsequent 
calculations.  T-statistics thus are interpreted relative to the mean effect rather than the 
omitted category.  
The resulting mean preference weights are used to estimate the MAR, the 
maximum acceptable risk, defined as the specific increase in treatment risk that exactly 
offsets the therapeutic benefit of a given improvement in treatment outcomes.  For 
example, consider a medication A that has a measured therapeutic benefit β1 = 0.5 
(versus surgery); and a value of βi = -0.025 for each 1% increase in infection risk.  The 
MAR for medication A is the increased risk of infection that exactly offsets the increase 
in satisfaction from preserving one’s colon.  Since offering medication A increases 
patients’ satisfaction by 0.5 versus surgery, if medication A increases the risk of infection 
by 0.5/0.025 = 20%, then the increased infection risk exactly offsets patients’ perceived 
satisfaction from avoiding surgery.  However, if medication A increases the risk of 
infection by <20%, then patients would be better off with medication A than with surgery.  
In practice, risk levels are fit to a generalized nonlinear function to utilize all information 
regarding the shape of the response gradient when determining the level of risk that 
makes the mean preference weight = 0 between categorical risk-level parameters. 
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 In our model, certain attributes were applicable only to the medication or surgical 
therapy option.  Furthermore, the surgical therapy option was inherently different from 
the medication therapy option.  Interaction terms and constraints in the model account 
for and measure the effect of surgery versus medical therapy in choice preferences for 
attributes.  The goal of the survey instrument was to calculate respondents’ willingness 
to trade off risk of SAE for improvements in UC symptoms through either medical or 
surgical therapy by calculating the MAR which respondents were willing to accept from a 
given medical therapy of specified efficiency to avoid a specific surgical outcome.  
Comparisons were made of the MARs for the lymphoma and serious infection SAEs in 
exchange for treatment efficacy to avoid surgical outcomes of an ostomy, a J-pouch with 
incontinence and a perfectly functioning J-pouch.  When computation of MAR required 
extrapolation beyond the upper level of risk presented in the survey, we report risk 
tolerance as greater than the level of risk shown.    
 Overall joint tests of parameter differences employed the scale-controlled 
likelihood-ratio test for choice models.153  Tests of differences of MARs used 2-tailed z-
tests for differences of means for independent, normally distributed random variables.  
Statistical differences between individual parameter estimates were tested using 
maximum-likelihood asymptotic 2-tailed tests at the 95% confidence level.  Subgroup 
analysis was performed utilizing an effects-coded model that included an interaction 
term with the most preferred parameter to maximize the statistical power of the subgroup 
models.  SAS 9.2 was used for data management and tables.  Limdep/NLOGIT 7.0 was 
used for statistical modeling.   
ETHICAL CONSIDERATIONS:  
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The study and final survey instrument were approved by the Institution Review Boards at 
participating institutions. 
RESULTS: 
Survey Population 
 Survey instruments were mailed to 662 patients and responses were received 
from 374 patients (56% response rate).  We had limited information on non-responders, 
but men were less likely to respond (data not shown).  Eight respondents (3%) answered 
the numeracy questions correctly but failed a test scenario in which there was a clearly-
dominated treatment choice.  Given the small number and their appropriate response to 
the numeracy questions, these patients remained in the analyzed final sample. After 
applying the exclusion criteria and excluding patients with missing answers to conjoint 
questions, 293 respondents were included in the final analysis (Fi
84 
 
gure 4.2).  Baseline demographics are shown in Table 4.2.  Notably, the majority of 
respondents was highly educated and had a long-standing history of UC.  Over half were 
in a remission as defined using the SSCAI or 6-point Mayo score.  The majority of 
respondents had previously or was currently taking an immunosuppressant medication, 
inclusive of thiopurine analog, calciurin inhibitor, methotrexate and/or anti-TNFα (Table 
4.2).   
Table 4.2:  Summary of Patient Characteristics* 
Characteristic Patients 
(N = 293) 
Gender, n (%) 
    Female 
    Male 
 
166 (57) 
127 (43) 
Age 
    Median 
    Mean 
 
45 years 
47 years 
Site n(%) 
    Dartmouth-Hitchcock Medical Center 
    Hospital of the University of Pennsylvania 
 
20 (7) 
273 (93) 
Ethnicity/Race n(%) 
    Caucasian 
    African-American 
    Asian 
    Latino 
    Other 
 
256 (87) 
17 (6) 
9 (3) 
2 (1) 
4 (1) 
Highest level of completed education, n (%) 
    Less than high school 
    High school or equivalent 
    Less than four years of college 
    4-year college degree (e.g., BA, BS) 
    Post-graduate studies 
 
1 (<1) 
32 (11) 
59 (21) 
91 (32) 
99 (35) 
Marital status, n(%) 
    Single/Divorced/Widowed 
    Married 
 
94 (33) 
189 (67) 
Desire for children, n(%) 
    Would like to have children in future 
    No desire/plans to have children in future 
 
80 (28) 
202 (72) 
Smoking status, n (%) 
    Current smoker 
    Past smoker 
    Never smoked 
 
15 (5) 
105 (38) 
160 (57) 
Length of time with UC 
    1+ years, n (%) 
    Mean, years 
    Median, years 
 
293 (100) 
13  
10  
Currently having active UC symptoms, n(%) 75 (27) 
When last active UC symptoms were experienced, n(%)  
85 
 
    Currently or within last 3 months 
    3-6 months ago 
    6 months to one year ago 
    Greater than one year ago 
70 (25) 
38 (14) 
41 (15) 
131 (47) 
Simple Clinical Colitis Activity Index < 2.5 56% 
6-point Mayo score < 1.5 64% 
5-ASA (oral and/or rectal) 
    Current use 
    Past use 
 
57% 
83% 
Corticosteroids (oral and/or rectal) 
    Current use 
    Past use 
 
10% 
70% 
Azathioprine/6-MP 
    Current use 
    Past use 
 
16% 
29% 
Cyclosporine and/or tacrolimus 
    Current use 
    Past use 
 
2% 
2% 
Methtrexate 
    Current use 
    Past use 
 
<1% 
3% 
Anti-TNF therapies (infliximab, adalimumab, certolizumab) 
    Current use 
    Past use 
 
15% 
22% 
Current or past immunosuppressant use (azathioprine, 6-
MP, cyclosporine, tacrolimus methotrexate, anti-TNF) 
 
54% 
Personal history of serious infection requiring 
hospitalization 
19% 
Knew family member and/or friend with serious infection 
requiring hospitalization 
23% 
Personal history of colorectal cancer 1% 
Knew family member or friend with colorectal cancer 36% 
Personal history of lymphoma 2% 
Knew family member or friend with lymphoma 19% 
Personally had history of bowel surgery with ostomy 13% 
Knew family member or friend with ostomy bag 17% 
Never discussed surgical options with medical or surgical 
physician 
51% 
Believe colonoscopies will prevent colorectal cancer 74% 
*Missing data excluded for each category 
 
Preference Weights 
 Analysis of respondents’ preference weights for the varying levels of mortality 
from lymphoma or serious infection over 10 years indicated a relatively steep decrease 
in DCE utility for all attributes when going from 0% to 0.5% risk compared to equivalent 
increments in levels of risk beyond 0.5% (Figure 4.3A).  This result is inconsistent with 
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the conventional preference-elicitation methods which assume linear preferences across 
probabilities; and indicate that participants perceived a much larger decrease in utility 
from going from “no risk” to “some risk” (such as 0.5%) than they did from moving from 
“some risk” to “some additional risk” (such as 2% or 5%).  Other researchers have 
identified similar risk-preference nonlinearities in non-health and health applications.61,62        
  Figure 4.3B shows the relative preference-weight estimates for the risk attributes 
and medication efficacy.  The estimated preference weights for risks and efficacies are 
consistent with the natural ordering of the levels.  The largest effect on DCE utility was 
for the difference between a J-pouch and ostomy when the participant selected the 
surgery option: no other change in risk levels was comparable to the perceived benefit of 
avoiding an ostomy when surgery was chosen as the preferred therapy for a UC flare.  
This difference in surgery type—J-pouch versus ostomy—influenced patients’ choices 
more than the risk of dying from lymphoma or serious infection, or medication efficacy 
over the ensuing 10 years when the medical therapy was chosen.  At the other extreme 
was medication efficacy:  the difference between a medication-induced remission and an 
incompletely effective medication that only improves disease activity to a mild state was 
roughly equivalent only to the difference between a 0% risk of lymphoma and a 0.5% 
risk.  Thus, on average, patients were willing to accept a 0.5% increase in risk of dying 
from lymphoma over 10 years if the medication put them in a complete remission.  
However, if the risk of lymphoma mortality over 10 years were higher, patients preferred 
a less effective medication with 0% risk of lymphoma.   
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 The mean MAR estimates of tolerance for SAE mortality risks respondents were 
willing to accept for better surgical or medication outcomes are shown in Table 4.3.  To 
avoid having an ostomy, patients were willing to accept more than 5% risk of dying from 
lymphoma over 10 years even if the medication was incompletely effective.  In contrast, 
patients were willing to accept only a 1-1.6% risk of death from lymphoma or serious 
infection for improved medication efficacy.  Patients were less tolerant of medication risk 
if the surgical outcome was a J-pouch; and remarkably, patients were equally satisfied 
with J-pouch surgery as with an incompletely effective medical therapy that left them 
with mild disease symptoms over 10 years (Table 4.3).    
Effect of Covariates on Benefit-Risk Tradeoff Preferences 
 Subgroup analysis was performed utilizing an effects-coded model and 
implementing an interaction on the most preferred parameter (Figure 4.4).  Disease 
duration, time from last flare (< 3 months) and disease activity overall had no impact on 
preferences for surgical versus medical therapy. There was a small subgroup of patients 
currently on immunosuppressant therapy who reported current active disease symptoms 
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(n=23), thus representing a compelling sample of patients facing possible surgery.  
Compared to those not on immunosuppressant therapy, these patients were less willing 
to accept ostomy surgery (p=0.04), but also less willing to accept the risk of lymphoma 
with medical therapy (p=0.03).  These findings are consistent with our overall findings of 
equivalent satisfaction with J-pouch surgery (but not ostomy) in the face of ineffective 
medical therapy and seem to indicate an influence of disease history on risk tolerance.  
Desire to have children did not influence the preference for surgical versus 
medical therapy; but females were significantly less willing to accept ostomy surgery 
(p=0.03).  Prior knowledge of the attributes did influence preferences: patients with either 
personal or first-hand knowledge of colectomy surgery were more willing to accept 
surgery overall (p=0.002) and less willing to accept ineffective medical therapies 
(p=0.007).  Those first-hand knowledge of serious infection, colon cancer or lymphoma 
were also more willing to accept surgery overall (p=0.006), although they were also less 
willing to accept ostomy as an outcome (p=0.02).  Additionally, those patients who had 
discussed surgery with a surgeon or physician were significantly more willing to accept 
surgery overall (p=0.03). 
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Impact of numeracy skills on results 
 Twenty-nine patients (9%) failed one or more of the numeracy tests.  These 
patients were excluded from the overall sample of 293 and assessed separately.  This 
group was significantly older than the baseline sample (median age 70 years), and 21% 
were African-American or described their race/ethnicity as “other.”  54% had a high-
school/GED education or less; only 22% had a 4-year college or higher education.  More 
were prior smokers (58%) and fewer (39%) had never smoked.  Finally, a large 
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percentage (83%) stated they had never discussed surgical options for their UC with a 
surgeon or physician; and this low-numeracy group expressed a stronger preference to 
avoid surgery compared to the remainder of the population (p=0.02, data not shown).   
 
DISCUSSION: 
 To our knowledge, this is the first study utilizing DCE to quantify patients’ trade-
off preferences for life-threatening adverse medication risks, surgical options and 
symptom relief in UC.  Using DCE, we found that patients were willing to accept high 
levels of serious adverse risk from medical therapy to avoid an ostomy.  However, 
patients also valued medication efficacy; indeed, if a durable clinical remission could not 
be achieved with medical therapy, patients were equally satisfied with J-pouch surgery. 
To our knowledge, this is the first empirical demonstration that UC patients without prior 
surgery view a well-functioning J-pouch as equivalent to persistent mild disease activity. 
Our results have several important implications.  First, patients expressed a 
willingness to accept tradeoffs among treatments of varying efficacies, risks of 
associated SAEs and surgical options in their responses to the DCE scenarios.  As 
expected, patients’ choices indicated a systematic preference for lower risk of SAEs and 
improved medication efficacy.  However, the preference to avoid surgery or SAEs 
outweighed concerns regarding medication efficacy.  During piloting, one-on-one 
interviews elicited a repeated sentiment that a disease flare associated with 
corticosteroid use was “acceptable” because it was a previously experienced risk, 
whereas the risks of a lymphoma, serious infection or surgery were much less familiar.  
The sentiment that rarer or poorly-understood risks are worse than more familiar risks is 
a well-studied phenomenon and the consistency of our results with this literature 
supports the face validity of our findings.154 
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Second, patients expressed a willingness to accept extremely high risks of SAEs 
to avoid a permanent ostomy or complications of a J-pouch.  However, not all surgical 
options were so strongly disregarded in preference for medical therapy:  UC patients 
were equally satisfied with an uncomplicated J-pouch surgery as they were with medical 
therapy, especially if that medical therapy was incompletely effective in maintaining a 
sustained remission (normal number of daily stools without blood or abdominal pain; and 
a good functional status without interference with work/daily activities) for 10 years. To 
the best of our knowledge, this is the first documentation of such a finding in UC.   
Our study’s finding that UC patients are willing to accept surgery as a treatment 
option for their disease is novel and has several important implications. First, it highlights 
that patient preferences can vary significantly from providers’ assumptions regarding 
these preferences. Current treatment algorithms have rested on the assumption of UC 
patients’ aversion to all surgical options; and indeed, prior conventional risk-assessment 
in UC supported this finding.50-54 Our findings underline the need for rigorous 
methodologies to accurately measure patient-preferences, and present several potential 
areas for further inquiry regarding UC patient preferences’ for their disease. As noted 
below, these findings and our methodological approach also have implications for 
diseases beyond UC, where physicians often make assumptions about patient 
preferences for risks and therapies in the absence of guiding data. 
Second, our study illustrates a critical unmet need in treatment discussions with 
UC patients. Shared decision-making and informed consent have increasing importance 
in the changing treatment algorithms for IBD.155  The majority of GI providers will 
escalate medical therapy for their UC patients due to failure of mesalamine to ensure a 
durable remission.8,14 However, our survey indicated that approximately 50% of patients 
with UC had never discussed surgical options for their UC with either a medical or 
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surgical physician, including 39% of patients with current or past immunosuppressant 
therapy use (data not shown).  Despite this, nearly 75% of our population indicated they 
felt they understood their surgical options very well or had minimal questions regarding 
surgery for UC (data not shown), indicating attainment of information from sources 
outside of their IBD care providers. Therefore, our findings that UC patients overall were 
willing to accept J-pouch surgery when faced with incompletely effective medical therapy 
clearly indicates a potential unmet need in treatment discussions with UC patients by all 
providers. Given the low surgery-discussion rate in our sample, our findings could also 
under-estimate UC preferences regarding surgical therapy, which may further bolster the 
importance of both discussions with patients and the acceptability of surgical options. 
Finally, this finding has important implications for testing efficacy of novel 
therapies.  These data suggest that for a medication to be preferred over J-pouch 
surgery, it needs to achieve sustained remission, not just a clinical response.  As such, 
remission may be the preferred outcome for testing efficacy of new therapies.  
 We also found that clinical history did influence preferences for therapies, 
including current and prior disease course, gender, knowledge of the attributes and 
discussion of surgery with a care provider.  It is important to note, however that the study 
design was not powered for precise sub-group analysis (as indicated by some large but 
non-significant ratios in the subgroup analysis Figure 4.4).  Given variable distribution of 
potential clinical characteristics, it is possible that other meaningful differences could not 
be discerned. 
DCE has significant advantages over other approaches to preference 
assessment.  Simple survey instruments which ask patients for their willingness to take 
medications fail to take into account alternative therapies or outcomes if the therapy is 
not taken.  Simple Likert-scale questions on the importance of separate interventions or 
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outcomes do not provide data on clinically relevant trade-off evaluations required in 
actual treatment decisions.  DCE mimics such actual decision-making by requiring 
respondents to evaluate tradeoffs in a realistic, although hypothetical, choice context.  
Alternative techniques such as standard gamble or time trade off elicit preferences for 
clinically unrealistic tradeoffs and assume that preferences are linear in time, linear in 
probabilities and identical across groups of patients, not allowing for health history or 
current health state to affect the relative importance of outcomes.  Our current study has 
shown that such assumptions are inaccurate for UC patients.   
 Our results are subject to several potential limitations and qualifications.  DCE is 
a simulated decision-making experience using hypothetical therapeutic options and 
therefore do not have the same medical, emotional and financial consequences of actual 
therapeutic decisions.  Therefore, patients may be more or less willing to accept risks in 
an actual clinical setting.  We sought to minimize this limitation with a series of patient-
level interviews and intense piloting to make the DCE trade-off scenarios as realistic as 
possible.  
The exercise of evaluating tradeoffs among multiple therapy options with multiple 
endpoints may be congnitively challenging.  However, we assessed the validity in 
participant responses through numeracy and logic tests, and the majority of our 
respondents (over 90%) passed these evaluations.  In particular, our study population 
had extensive experience with UC, was overall well-educated, and included a large 
proportion with personal knowledge of many of the attributes, thus strengthening the 
validity of their preferences of choice options in the DCE survey.  However, in our study, 
those participants who failed the numeracy exams had essentially uninterpretable 
results. Therefore, extrapolation of our results to low-numeracy populations should be 
done with caution. 
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Our patients were seen by a variety of physicians from tertiary-care centers; and 
the majority had escalated medical therapy.  While this may limit generalizability, our 
sample would seem to typify the UC patient who has exhausted 5-ASA therapies and 
now faces decisions regarding immunosuppressant use versus surgery for further UC 
flares. Many of these patients are seen by community and local practices; thus, our 
findings have applicability beyond referral centers. 
 Both SAEs associated with medical therapies and surgical outcomes are 
probabilistic in the real clinical setting.  However, in piloting, including conditional 
probabilities (the probability of an SAE conditional on the probability of having the 
outcome) led to significant patient confusion.  This was likely related to known difficulties 
with conditional-probability numeracy skills in the general population.  Therefore, to 
minimize this bias, we presented surgical outcomes as certain and presented SAEs as 
mortality associated with the SAEs.  Our estimates therefore cannot be interpreted as 
MARs for uncertain benefits or outcomes at the individual patient level, and therefore 
must be interpreted with caution.  However, we sought to evaluate the MARs over the a 
plausible distribution of potential SAEs related to medical therapy, or over the potential 
distribution of surgical outcomes, so that despite these simplifying assumptions, these 
aggregate estimations may be informative for decisions regarding benefit-risk tradeoffs 
for populations of UC patients.   
 Similarly, the outcome of pouchitis is a conditional outcome of J-pouch surgery; 
and is further conditional in its chronicity with some having an isolated episode while 
others have a more chronic course. To avoid such complicated calculations, we chose 
not to include the risk of pouchitis as an attribute. However, we did include incontinence 
which may serve as a surrogate for some of the clinical symptoms of pouchitis (including 
bowel frequency and incontinence).  To the extent that fear of pouchitis might dissuade 
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patients from having pouch surgery, the MAR for infection and lymphoma relative to 
pouch surgery could be viewed as underestimates. However, for these patients, 
incontinence would be expected to be a worse outcome than pouchitis, and therefore the 
estimated MAR for J-pouch surgery with pouchitis can be extrapolated to fall between 
incontinence and a perfectly-functioning J-pouch. 
 Our attributes were within a 10 year time horizon for both risks and efficacy.  This 
helped to avoid requiring respondents to interpret extremely small probabilities.  
Furthermore, when medical therapies such as thiopurines or anti-TNF therapy are 
initiated, the plan typically calls for chronic therapy as long as the medication remains 
effective.  Similarly, colectomy is irreversible. Although assuming that UC would remain 
in remission or mildly active for a full 10 years is an over-simplification of the natural 
history of medically treated UC, one can view these results as if the average disease 
activity was mildly active or inactive for the 10 year period.  Thus, the 10 year time 
horizon presented in this discrete choice model provided for improved patient 
understanding and was consistent with the time frame appropriate for the clinical 
decision.   
 In conclusion, we have applied a novel methodology to quantify UC patients’ 
treatment preferences with striking findings.  Patients preferences are most strongly 
impacted by the type of surgical outcome:  patients are willing to accept medications that 
have relatively high risks of fatal complications to avoid a permanent ostomy or 
incontinence.  Our findings therefore lend quantifiable evidence that support current 
treatment paradigms that involve pursuance of medical therapies to avoid these surgical 
outcomes.  This rigorous methodology also can aid regulators in understanding patients’ 
evaluation of the risk of SAEs for future medical therapies in the context of potential 
therapeutic benefit. 
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Even more striking, however, UC patients are equally satisfied with an 
uncomplicated J-pouch as they were with a medication that has very small risks of fatal 
complications or a medication that is incompletely effective at sustaining a durable 
clinical remission.  Traditionally, clinical trials of new therapies have evaluated two 
endpoints--clinical response and clinical remission.  Our findings indicate that when 
evaluating new therapies or therapeutic algorithms, the primary outcome should be a 
clinical remission rather than a clinical response. Given that patients are equally satisfied 
with surgery as with mild disease activity, and the goal of medical therapy is to achieve 
greater patient satisfaction than with surgery, our findings also indicate a critical unmet 
need to improve physician-patient communication regarding realistic expectations of 
medical and surgical therapies.  
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CONCLUSIONS 
UC represents a unique type of IBD in which there is the potential for a cure; 
however, this is a surgical cure with an imperfect quality of life.  The past few decades 
have seen an increasing array of immunosuppressive medical therapies for UC, and the 
upcoming years bring promise of additional such therapies.  Inherent in the development 
of these therapies, and in current treatment paradigms, is the assumption that UC 
patients’ prefer to avoid colectomy surgery at all costs.  However, as medical therapy in 
UC has continued to progress, so has the appreciation for the SAEs associated with 
these therapies as well as the inconsistent durable efficacy of these therapies for a 
lifelong disease.  This begs the question, “What if medical therapy is not right for 
everyone?  At what point are UC patients unwilling to accept chronic medical therapies 
for their UC, and more willing to accept a surgical cure?”   
To address this question, traditional patient risk tolerance studies have been 
conducted with results that would support the notion that UC patients view colectomy 
surgery as an option of last resort.  However, these traditional methods for measuring 
risk tolerance have inherent flaws that may bias their estimates of patient preferences.  
While economic theory has advanced the methodologies used to quantify utility 
estimation and risk-benefit tolerance, these advanced methodologies have not been 
applied to the question of medical versus surgical therapies in UC.  We recognized that 
such studies are critical in this field, where current treatment guidelines rest solely on 
such assumptions of patients’ intolerance for surgery; and where the risks of chronic 
medical therapy can have life-threatening consequences.  We therefore sought to apply 
DCE to accurately quantify UC patients’ risk-tolerances for medical and surgical therapy 
in their disease.   
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We began by defining all-cause and cause-specific mortality in UC in the most 
comprehensive meta-analysis performed to date.  Our findings are the first to 
demonstrate an increased all-cause mortality rate relative to the general population, a 
finding that itself is worthy of additional investigation.  We also found increased cause-
specific mortality from CRC, pulmonary disease and nonalcoholic liver disease in UC.  
Further investigation is warranted to elucidate specific causes of these elevated mortality 
rates.  To this end, we have conducted initial analysis in the area of overall mortality with 
a study comparing relative survival of UC patients with moderate-severe disease 
pursuing chronic medical therapy versus elective colectomy surgery.  Our finding of an 
increased mortality in UC patients with moderate-severe disease pursuing chronic 
medical therapy supports earlier limited studies addressing this question, and raises 
important questions about the two treatment strategies, especially in the setting of the 
findings from our DCE work.38,39,156   
Additional studies are also needed aimed at evaluating pulmonary-related and 
liver-related mortality.  It is interesting to note that CD patients in particular also had an 
elevated liver-related mortality.  Traditionally, liver-related disease in IBD was believed to 
be secondary to primary sclerosing cholangitis (PSC), a rare disease most commonly 
associated with UC.  It is possible that the elevated liver-related mortality is not 
exclusively due to PSC but perhaps due to other causes of liver disease.  Those with 
IBD are also at risk for liver diseases that affect the general population.  The most 
common of these conditions is that of non-alcoholic fatty liver disease;121 and recently 
there has been an intriguing association between visceral fat and IBD, specifically CD 
activity.157,158  These findings raise the question of whether fatty liver disease is a cause 
or a consequence in IBD.  Specifically, it is possible that active IBD increases visceral 
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and hepatic fat.  We are currently conducting analysis to investigate underlying rates of 
non-alcoholic fatty liver disease in IBD and correlate it with disease activity and 
increased visceral adiposity.  Pulmonary-related mortality in IBD may be related to lack 
of tobacco cessation in this population; or related to increased pulmonary-related 
infections, especially in the setting of increased immunosuppressant use.  Results from 
further studies investigating these potential causes of elevated mortality in CD and UC 
could inform improved interventions such as vaccines, dietary therapies, or even 
improved informed consent for IBD patients when making decisions regarding therapy 
options for their disease.   
While not the primary purpose of our meta-analysis, our study also demonstrated 
that inception-based cohorts and population-based studies yielded very similar overall 
mortality estimates in IBD.  It has been widely believed that inception-based cohorts 
were superior to population-based studies in evaluating mortality.  Our findings suggest 
the potential for greater inclusion of population-based studies in these investigations, 
which may allow for data enrichment from cohorts not otherwise utilized.   
Assessing disease severity in UC without direct physician contact was critical to 
our DCE study.  Non-invasive clinical disease assessment has been a challenge, due to 
cumbersome and complicated patient-driven disease activity indices such as the SCCAI.  
We evaluated a simple 2-question patient-driven non-invasive disease activity index, the 
6-Point Mayo, and found it to have good correlation, sensitivity, specificity and predictive 
value compared to the SCCAI.  We further validated this in a separate cohort of UC 
patients and found similar results even when stratified by varying disease extent 
(pancolitis versus left-sided colitis).  Finally, we conducted analysis adding back 
components of the SCCAI to determine if the 6-Point Mayo could be improved with any 
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single SCCAI component.  We found that the components of urgency and general well-
being improved the 6-Point Mayo’s predictive value.  Overall, these supplemental SCCAI 
components contribute very little additional burden to the 6-Point Mayo, thus allowing 
clinical investigators a simple non-invasive tool to assess disease activity without direct 
physician contact.  With the increasing number of clinical studies in UC, this promises to 
be a very important tool for researchers.  
In our study, we did find a poor correlation between the non-invasive patient-
driven indices and a purely endoscopic evaluation of UC disease activity.  It is well-
known that endoscopic, and even histologic, active disease is often found in patients 
who are asymptomatic.  With an increasing awareness of the importance of mucosal 
healing in IBD, this disconnect between patient symptoms and endoscopic activity leads 
to important future questions.  It is likely that different parameters govern patients’ 
willingness to accept additional medical therapy risks to improve mucosal healing and 
presumably prevent future disease relapses, especially in the setting of asymptomatic 
clinical disease.  We are currently conducting DCE analysis evaluating patients’ risk 
tolerances in this setting.  The findings of this study will have important impact in therapy 
algorithms for IBD patients, including defining potential thresholds for therapy efficacy 
and SAEs to achieve mucosal healing.   
Finally, we have conducted the first DCE study evaluating UC patient risk 
tolerances for medical therapy SAEs to avoid colectomy surgery with varying treatment 
efficacy.  We have shown, for the first time, that when facing incomplete durable clinical 
remission with medical therapy, UC patients are equally willing to accept J-pouch 
surgery.  Additionally, this study illustrates that UC patients do value the difference 
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between remission and clinical response, and suggests that the former should be the 
preferred outcome when evaluating therapies in UC. 
Our work emphasizes that UC patient preferences for disease therapy can vary 
significantly from providers’ assumptions regarding their preferences; and questions the 
traditional therapy algorithm in UC of exhausting all medical therapy before considering 
colectomy surgery.  Taken together with increasing evidence that elective colectomy 
may have a survival benefit in moderate-severe UC,38,39,156 the current work supports 
early discussion regarding surgical options for UC patients.  In our current work, the 
majority of UC patients indicated a lack of discussion regarding surgical options for their 
UC in their current medical care, a finding previously supported by other studies.159-161 
There are several possible reasons for this.  UC patients may reject considering surgery 
as a valid option due to pre-formed notions regarding surgery in general.  
Gastroenterologists may not have time to discuss surgical options for their patients, and 
may make it a low priority in therapy discussions.  This may be especially true given the 
traditional view held by gastroenterologists that UC patients want to avoid surgery at all 
costs.  Finally, gastroenterologists may not sufficiently or accurately depict surgery in a 
way that makes UC patients comfortable with their discussion.  In our prior work, we 
examined what factors were associated with UC patients reporting that they “felt very 
comfortable with their understanding of the surgical options for their UC and had no 
further questions regarding surgery.” The only statistically significant variable associated 
with UC patients reporting satisfactory understanding with UC surgery was discussion 
with a surgeon—not a gastroenterologist.159    
Our work has therefore illustrated a critical unmet need for improved surgical 
education and discussion in UC.  If UC patients are averse to the risks of medical 
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therapy, but lack sufficient knowledge about the surgical options for their UC, 
educational interventions are crucial to facilitate shared decision-making and informed 
consent.  One of the most important roles of education is to help patients weigh medical 
therapy risks against the risks of surgical therapy.  This informed decision-making has 
even greater value in the setting of incompletely effective medical therapy that risks 
continued active disease.  Education could alter patients’ readiness to choose colectomy 
instead of medical therapy.  This takes on even greater impact given the potential for 
improved survival with elective colectomy compared to chronic ineffective medical 
therapy, which entails continued risks of active symptoms and/or need for corticosteroid 
therapies.  For example, given the low surgery-discussion rates in our current work, our 
findings could under-estimate UC preferences regarding surgery therapy:  it is possible 
that UC patients may be more willing to accept ostomy surgery; and may even prefer J-
pouch surgery to chronic ineffective medical therapy.   
We are currently working on an online patient-driven educational tool for UC 
patients with a dedicated surgery component.  We have also designed a DCE-based 
study to evaluate the impact of this tool on UC patient risk tolerances.  Rigorous 
methodologies to assess the effect of educational interventions on decision-making by 
UC patients have not previously been performed, and thus the impact of such 
educational interventions is unknown.  This information can enhance and validate our 
proposed educational tool in UC.  It can also set metrics for future educational tools in 
UC (or in IBD) as well as establish a rigorous methodology to assess efficacy and impact 
of future tools in IBD. 
Our current work in UC patient risk tolerance assessment also highlights the 
need for rigorous assessment of patient preferences.  The findings of our DCE study are 
104 
 
in contrast to the findings from more traditional—but methodologically flawed—systems 
for assessing patient risk preferences.  However, DCE is not without potential limitations 
including one inherent to its approach, namely that it remains a simulated decision-
making experiment.  Patients may be more or less likely to accept risks in actual clinical 
settings.  Revealed-preference (RP) is a method of obtaining measured utilities based 
upon actual decision-behaviors.  However, because RP data is based on actual choices, 
large numbers of observations are needed and data quality is limited:  data only reflects 
existing therapy options, and may reflect mixed preferences including those of patient, 
physician and payer.  
While many studies have shown good concordance between DCE and RP 
measured risk preferences and the successful ability to merge these data in 
transportation and environmental research,162-165 to date only one study has evaluated 
such joint estimation in health care.166  UC represents a unique opportunity for health-
care based joint DCE-RP data enrichment.  Treatment decisions regarding medical 
versus surgical therapy are dominated by UC patient preferences regarding surgery. 
Understanding external forces that shape these preferences can inform measured 
patient preferences.  We have currently proposed a study to utilize our existing I3 
database to combine DCE with RP decisions made in real clinical settings.  This joint 
estimation of preference choice data will have several significant impacts:  this will allow 
for real-world statistical discrimination of UC patient risk tolerance; it can allow for the 
identification of new attributes affecting UC patients’ risk tolerance; it will allow 
refinement of DCE measured tolerances to be reflective of revealed behavior; and it can 
inform DCE data-enrichment methodology in other chronic diseases and treatment 
preferences. Fundamentally, patient preferences play a key role in their satisfaction and 
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willingness to accept and adhere to therapies, which in turn influences clinical outcomes. 
Thus, improved methodologies in risk estimation can help answer the question, “Why 
are UC patients not having surgery, and what can be done to improve medical and 
surgical therapy options for UC patients?” 
In summary, we have completed a set of experiments that challenges and 
changes the way we view the prognosis of UC, how we measure UC disease activity, 
the methodologies used to quantify UC patient risk preferences, and the way we view 
treatment algorithms in UC.  We have determined all-cause and cause-specific mortality 
in UC, and investigated methodological tools used to measure these outcomes.  We 
have investigated and validated a simple patient-driven tool for assessing UC disease 
severity.  Finally, we have challenged the traditional view that UC patients wish to avoid 
colectomy surgery at all costs as well as the conventional methods used to quantify UC 
patient preferences for medical and surgical therapies in UC.  Our work has immediate 
direct impact for UC patients, providers and health-care administers; and it further 
informs many important future research questions regarding UC therapies, treatment 
algorithms, and patient decision-making. 
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